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ABSTRACT 
Tsai-Ling Liu: Management and Outcomes of Patients with Cirrhosis and Diabetes  
(Under the direction of Justin Trogdon) 
 
Cirrhosis of the liver is a leading cause of morbidity and mortality in the United States. The number 
of patients with cirrhosis is expected to increase driven by the dual epidemics of diabetes and obesity 
leading to nonalcoholic fatty liver disease. Approximately 40% of patients with compensated cirrhosis 
have diabetes. Patients with both cirrhosis and diabetes may have an increased risk of decompensation 
events (i.e., ascites, spontaneous bacterial peritonitis, variceal bleeding, and hepatic encephalopathy), 
hepatocellular carcinoma, and acute renal failure. However, large studies of dually-diagnosed patients’ 
risk of decompensation over time are lacking (Aim 1). Given the complexity of these dual comorbidities, 
dually-diagnosed patients may be managed more effectively by multiple physician specialties including 
primary care physicians (PCPs), and/or specialists such as gastroenterologists (GIs) and endocrinologists 
(ENDOs). However, little is known about who cares for these patients. This study seeks to better 
understand the treatment practices (Aim 2), and how physician mix affects the care and health outcomes 
of dually-diagnosed patients (Aim 3).   
Patients aged 18 years and older with compensated cirrhosis and diabetes were identified through 
2000 – 2013 Marketscan® Commercial Claims and Encounters and Medicare Supplemental Database. 
Patients with decompensated cirrhosis, HIV/AIDS, or liver transplantation prior to first diagnosis of 
cirrhosis (Aim1) and first dual diagnosis (Aims 2 and 3) were excluded. The analytical approach included 
logistic regression and Cox proportional hazard models (Aim 1), a multinomial probit model (Aim 2), and 
logistic regression with a two-stage residual inclusion (Aim 3).   
The study found that patients dually diagnosed with compensated cirrhosis and diabetes had a 
higher risk of having decompensation events than patients with cirrhosis only. A large proportion of dually-
diagnosed patients visited only PCPs. Dually-diagnosed patients who were managed by both PCPs and 
GI/ENDOs had better outcomes. These findings suggest that careful management of diabetes in patients 
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with liver disease may reduce the risk of clinical decompensation in this population. Our findings support 
the importance of cross-specialty care, which is central to Patient-Center Medical Homes.
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CHAPTER 1. OVERVIEW OF MANAGEMENT AND OUTCOMES OF PATIENTS WITH CIRRHOSIS 
AND DIABETES 
 
INTRODUCTION 
Liver cirrhosis is a chronic liver disorder that causes significant global health burden.1 In the 
United States, cirrhosis was the eleventh causes of death in 2012.2  Recent literature suggests that more 
than 600,000 U.S. adults suffer from cirrhosis, yet up to 70% of patients are unaware of their diseases.3 
Although the inpatient mortality rate has slightly decreased by 5% in the past decade due to improved 
inpatient care,4 cirrhosis is still the top ten leading causes of death among working-age population (age 
25-64) in 2012.5 Moreover, the direct cost of cirrhosis/fibrosis in the U.S. was estimated to be $1.8 billion 
in 2009.6 Cirrhosis consists of two stages: compensated cirrhosis, where the liver may slowly lose 
function, versus decompensated cirrhosis, where patients develop complications and require intensive 
medical care. Without proper care, compensated cirrhosis can easily lead to decompensation (i.e., 
variceal hemorrhage, ascites, and hepatic encephalopathy, hepatocellular carcinoma) and even acute 
renal failure. Once decompensation occurs, the 5-year mortality can reach 85% without transplant.7  
Diabetes is highly prevalent among patients with compensated cirrhosis (approximately 40% on 
average).8–10 Studies have indicated that diabetes is associated with certain etiologies of cirrhosis,11 and 
the number of patients with cirrhosis is expected to increase driven by the dual epidemics of diabetes and 
obesity leading to non-alcoholic fatty liver disease.12 Although the evidence on the relationship between 
cirrhosis and diabetes is emerging and not yet definitive,13–19 many studies has shown that patients with 
cirrhosis who are also diagnosed with diabetes have increased risk of developing decompensated 
cirrhosis or hepatocellular carcinoma, as well as increased mortality.13–18 However, most of these studies 
were conducted using relatively small samples in other countries. The studies conducted in the U.S. 
either focused only on the correlation between diabetes and hepatocellular carcinoma among elderly 
patients with cirrhosis,20 or only on patients in the Department of Veterans Affairs (VA).12,21 Hence, 
whether patients dually diagnosed with compensated cirrhosis and diabetes truly have an increased risk 
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of decompensated cirrhosis still needs to be confirmed in a larger sample study, especially among 
patients of working age.  
In addition, given the complexity of these dual comorbidities, this group of patients may be 
managed more effectively by a mix of physicians including primary care physicians (PCPs), 
gastroenterologists (GIs), and endocrinologists (ENDOs). However, little is known about who currently 
cares for these dually diagnosed patients.22 Although there are some studies on physician mix among 
diabetic patients with chronic kidney disease and tuberculosis,23–26 or among patients with cancer,27–31 
studies are still lacking for physician mix among patients who were dually diagnosed with cirrhosis and 
diabetes. Among the patients with diabetes in the U.S., over 70% of visits were with primary care 
physicians (including family practice, general practice, and internal medicine). Moreover, another 20% of 
visits among patients with diabetes were treated by specialties other than endocrinology, while only about 
8% of visits were with endocrinologist.32 However, we do not know whether patient outcomes are better 
when patients are managed by PCPs, specialists (i.e., GIs and ENDOs) or both. There remains a need to 
better understand who is managing these dually diagnosed patients, and whether being treated by a mix 
of physicians improves dually diagnosed patients’ health outcomes.  
The long-term goal of this research is to improve the understanding of management and 
outcomes of patients dually-diagnosed with compensated cirrhosis and diabetes. The overall objective 
was to study the effect of diabetes with compensated cirrhosis on health outcomes, describe the mix of 
physician specialties treating these complex patients, and to determine the impact of visiting different 
physician specialties on the likelihood of a patient experiencing a decompensation event or 
hospitalization. My central hypothesis was that patients who were dually diagnosed with compensated 
cirrhosis and diabetes have higher likelihood of experiencing any decompensation event. Among patients 
who were dually-diagnosed with compensated cirrhosis and diabetes, there is still a large proportion of 
patients visited only PCPs but not any specialists regardless of their complex conditions. Moreover, these 
complex patients may have the lowest likelihood of experiencing a decompensation event and/or all-
cause hospitalization when treated by both PCP and GI/ENDO. The rationale for this study was that 
patients who were dually diagnosed with compensated cirrhosis and diabetes have complicated health 
status and require more health care attention from multiple physician specialties to maintain their health. 
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Without care from the specialists (i.e., GI and/or ENDO), patients may not be able to receive sufficient 
health care and thus, have higher risks of getting decompensation events than their counterparts. This 
leads to the following three aims and hypotheses to be tested using the Truven Marketscan® Commercial 
Claims and Encounters and Medicare Supplemental Database. 
1. To determine whether patients dually diagnosed with compensated cirrhosis and diabetes are 
more likely to experience a decompensation event than patients diagnosed only with 
compensated cirrhosis. 
Hypothesis: Patients with both cirrhosis and diabetes are more likely to experience a decompensation 
event than patients diagnosed only with cirrhosis. Patients with cirrhosis and diabetes have more 
complex conditions than those who only have cirrhosis. If this is the case, patients who were dually 
diagnosed with compensated cirrhosis and diabetes may need a higher level of care or more 
coordinated care. 
2. To determine what physician specialties are treating patients dually diagnosed with 
compensated cirrhosis and diabetes.  
Hypothesis: Regardless of the complexity of their health condition, there is still a large group of 
patients who did not receive care from both PCP and GI/ENDO. Patients with cirrhosis and diabetes 
may be treated by a PCP, a GI, an ENDO, or combination of these three groups with any other 
specialists. This aim will provide information about the treatment practices for these patients, and 
particularly, the extent to which a mix of physicians is employed in their care between 2000 and 2013.  
3. To determine whether care from PCP, GI and/or ENDO for dually diagnosed patients with 
compensated cirrhosis and diabetes results in a lower likelihood of experiencing a 
decompensation event and/or all-cause hospitalization when compared with dually diagnosed 
patients were not treated by both PCP and GI/ENDO.  
Hypothesis: Patients who were treated by both PCP and GI/ENDO will have the lowest likelihood of 
experiencing a decompensation event and/or all-cause hospitalization compared to those who were 
not treated by a combination of these specialists. Four physician mix categories were created: (1) 
PCP with no GI/ENDO, (2) GI/ENDO with no PCP, (3) both PCP and GI/ENDO, and (4) neither PCP 
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nor GI/ENDO. This aim will be able to support continued emphasis on improving coordination of care 
through care models such as patient-centered medical homes. 
With the increasing burden of patients with cirrhosis, managing their health and comorbidities is a 
major challenge. This project aims to provide evidence on how visiting different physician specialties 
among dually-diagnosed patients with compensated cirrhosis and diabetes may influence their health 
outcomes. The results will provide the information to support the coordination between physician 
specialties on disease management, especially among patients with multiple chronic conditions.    
BACKGROUND  
The main cause of cirrhosis in the U.S. is the aging baby boomers with chronic hepatitis C and 
increased prevalence of fatty liver disease.33,34 As people who were born during 1945-1965--those who 
were highly likely to have hepatitis C infection--grow older, the number of HCV-related cirrhotic patients is 
estimated to double in the next ten years.35–37 Heavy alcohol consumption was commonly observed 
among these patients, which causes alcoholic fatty liver disease.34 At the same time, the estimated 
prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly in the U.S. in the past 
decade.38,39 According to a recent study, the prevalence of NAFLD was 19%, accounting for 28.8 million 
people.39 These patients are free from viral hepatitis infection (e.g., hepatitis B or hepatitis C), but are 
increasing paralleled with the prevalence of diabetes.38 On the other hand, diabetes has been recognized 
as an independent prognostic factor on developing cirrhosis.40  Approximately 40% of patients with 
cirrhosis also have diabetes.8 
Given the complexity of these patients’ conditions, they may be more effectively managed by a 
mix of PCPs and specialists from gastroenterology and endocrinology. One previous study found that 
over 70% of patients with diabetes were managed by PCPs,32 but few studies had focused on 
management on patients with cirrhosis.41–43 One study has shown that the role of PCPs in managing 
patients with compensated cirrhosis was to identify risk factors, improve quality and length of life, and 
prevent patients from complications.41 The role of specialists is to traditionally treat the complications and 
select patient candidates for liver transplantation when necessary.41 Although one study found that 
patients had better outcomes when managed by both PCPs and GIs when admitted to hospital due to a 
decompensated cirrhosis event,42 and another showed that local access to subspecialty care increases 
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the chance of patients receiving a liver transplant,43 evidence is lacking about the association between the 
combination of physician specialties and health outcomes among dually-diagnosed patients. How to 
manage these complex patients and maintain their health is a major public health concern in the near 
future.  
With the implementation of the Affordable Care Act, strategies to coordinate care, including 
Patient-Centered Medical Homes (PCMH) are widely emphasized.44,45 One main principle that PCMH 
emphasize is coordinated and/or integrated care between PCP and specialists.46 Studies have found that 
visits to multiple physician specialties can directly affect quality of care. Specifically, the involvement of 
PCPs in addition to specialists improves preventive care among cancer survivors.28–31 In addition, 
previous studies have also found that patients residing in higher physician density areas had better 
access to PCPs and specialties.43,47,48 Despite the rapid increase in the number of patients with multiple 
chronic conditions,49 little is known about the mix of PCP and specialists who treat these patients. 
Therefore, the three aims in this project focus on the association between management and outcomes 
among dually-diagnosed patients.   
CONCEPTUAL MODEL 
The conceptual model for this study (Figure 1.1) is based on the Andersen Health Care Utilization 
Model.50 This model was initially developed as the behavioral model to measure whether people equally 
access health care in late 1960s. After several phases of modification, the final model included outcomes 
and emphasized the dynamics of health care services use from environmental factors to individual 
factors, including feedback loops. Three factors that may affect health care services use in the model are 
1) predisposing factors (i.e. demographic characteristics such as age, gender, and socio-economic 
status); 2) enabling factors, which affect patients’ health care utilization (i.e. physician specialty, 
geographic location, metropolitan statistical area (MSA), and Medicare coverage); and 3) need (perceived 
vulnerability, such as number of comorbidities and drug usage).  
When a patient is diagnosed with both cirrhosis and diabetes, their need for health care services 
is expected to be higher. Their predisposing characteristics (demographic characteristics) are fixed, but 
their enabling factors might change over time. In this case, even though these patients’ health conditions 
become more complex and the need for health care services is increasing, patients might not change 
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their use of health care services quickly, which will lead to decompensation events and higher 
hospitalization rate than those who are only diagnosed with cirrhosis. Therefore, I hypothesize that 
patients with cirrhosis and diabetes are more likely to experience a decompensation event than patients 
diagnosed only with cirrhosis (Aim 1). With the hypothesis that patients continue to use the same health 
care services due to access and financial barriers, the majority of dually diagnosed patients only see his 
or her PCP and do not visit any GI and/or ENDO, regardless of the complexity of their deteriorating health 
condition (Aim 2).  
Once patients change the pattern of health seeking behavior after being diagnosed with cirrhosis 
and diabetes, their enabling resources and needs change accordingly. These patients will receive medical 
advice from different professionals and will obtain better care management through multiple physician 
specialties.29,51 Moreover, with more involvement from multiple medical professionals, patients may have 
more detailed check-up to better understand their health status and the diseases, thus, have higher 
chance for good outcomes. Therefore, I hypothesize patients who were treated by a PCP, a GI and/or an 
ENDO have lower likelihood of experiencing a decompensation event and/or all-cause hospitalization 
than patients who were not treated by both types of specialties (Aim 3).  
Many predisposing characteristics can also influence health outcomes. For instance, males and 
the elderly have higher risk of liver cirrhosis mortality than their counterparts.1 Moreover, literature has 
also shown that the number of patients with cirrhosis admitted to hospitals in the South are significantly 
higher than other regions of the U.S.52 In addition, past health history and the number of comorbidities of 
each patient may also affect patient’s choice of care and influence their health outcomes. All these factors 
will be considered during the study of this topic. 
SIGNIFICANCE 
The study is the first to provide nationally-based evidence, especially among working-age 
population, that diabetes in patients with cirrhosis is correlated with higher risk of 
decompensation events. Cirrhosis has been a major cause of total hospitalizations for chronic liver 
disease, which have increased by 14% since 2000.6 Literature has shown that patients with cirrhosis have 
a higher risk of getting decompensated cirrhosis or even hepatocellular carcinoma when the patients are 
diagnosed with diabetes;13–15,17,18,20 however, these studies were all conducted using relatively small 
 7 
samples outside of United States14,15 or only among an elder population.13,17,18,20 Therefore, this study 
illustrates the magnitude of impact on having diabetes in addition to compensated cirrhosis in a nation-
wide, working-age population. 
The study identifies the current mix of health care physicians among dually-diagnosed 
patients with compensated cirrhosis and diabetes. With the increasing burden of patients with both 
conditions, understanding the current patterns of visiting physician specialties among patients who were 
dually diagnosed with compensated cirrhosis and diabetes is needed. As health care reform proceeds, 
understanding the management and outcomes provided by multi-specialty physicians among patients 
with multiple chronic conditions is important. This study will provide the opportunity to use nationally-
based evidence to understand the current pattern of care for dually diagnosed patients with compensated 
cirrhosis and diabetes.  
The study examines how the mix of physician specialties, consisting of a PCP, a GI, and/or 
an ENDO, influences dually diagnosed patients’ outcomes. With the increasing burden of treating 
patients with cirrhosis, managing dually diagnosed patients with cirrhosis and diabetes is one major goal 
in public health. However, current studies on visiting multi-specialty physicians have mainly focused on 
patients with cancer.29–31 Moreover, those studies were focused only on a single type of cancer and with 
the effect of visiting a mix of physician specialties on the quality of preventive care. To our knowledge, 
there are no studies focused on multi-specialty physician care on patients with cirrhosis nor patients who 
were dually diagnosed with multiple chronic conditions.22 Therefore, this study is able to examine how 
visiting multiple physician specialties can improve both health outcomes and health care utilization for 
dually diagnosed patients.    
INNOVATION  
This project is innovative in three important ways. First, this study assesses how the mix of 
physician specialties influence dually diagnosed patients’ outcomes. The results of this project 
provide evidence on visiting multi-specialty physicians among patients with other chronic 
conditions. Literature that assessed physician mix categories has only focused on patients with a single 
disease (i.e. cancer) and on their preventive care services. However, the majority of patients nowadays 
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have multiple chronic conditions that require more intensive care.53 This study’s innovation is to examine 
the pattern of physician care among patients with multiple chronic conditions (i.e. compensated cirrhosis 
and diabetes).      
Second, this study uses physician density as an instrumental variable in assessing the 
physician mix categories among patients with multiple chronic conditions. Patients who visited 
multiple physician specialties may be sicker in unobserved ways, which introduces selection bias. 
However, due to data limitations, we were unable to fully measure patients’ disease severity. Therefore, 
to avoid unobserved selection bias, this study uses instrumental variables (i.e., physician densities) to 
assess the odds of experiencing decompensation events when seeing a different mix of physicians 
among patients with multiple chronic conditions. 
Third, this study uses nationwide health care claims data to provide a more generalizable 
result to the U.S. population. The largest U.S. studies of diabetes and decompensation events were 
clinic- or hospital-based data, which had small sample sizes,54 or come from the veteran population and 
may not be generalizable to the population most likely to be affected by cirrhosis.12 One study was based 
on SEER-Medicare data and focused only on the elderly population.20 Therefore, using nationwide health 
care claims data such as MarketScan allows us to obtain more representative results and provide the first 
evidence among working-age, civilian population. 
SUMMARY 
Cirrhosis of the liver is a leading cause of morbidity and mortality in the United States. Patients 
with both cirrhosis and diabetes may have an increased risk of decompensation events (i.e., variceal 
hemorrhage, ascites, and hepatic encephalopathy), hepatocellular carcinoma, and acute renal failure. 
However, outcome studies with large samples of patients dually diagnosed with compensated cirrhosis 
and diabetes and their risk of decompensation over time are lacking. Moreover, given the complexity of 
these dual comorbidities, this group of patients may be managed more effectively by a mix of physicians 
including a PCP, a GI, and/or an ENDO. However, little is known about who currently cares for these 
dually-diagnosed patients, as well as how different mixes of physicians affect patient outcomes. By 
understanding the physician visit pattern among patients with compensated cirrhosis and diabetes from 
this study, we can provide more appropriate strategies to manage and improve their health. Moreover, 
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findings from this study will also provide evidence on the importance of the collaboration between PCPs 
and specialists, especially when managing patients with multiple chronic conditions.   
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Figure 1.1 - Andersen Health Care Utilization Model 
 
  Environment Population Characteristics Health Behavior Outcomes 
Figure 1.1. Andersen Health Care Utilization Model 
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CHAPTER 2. METHODS 
 
DATA SOURCES 
Data used for this study were obtained from MarketScan® Commercial Claims and Encounters 
and Medicare Supplemental Databases from the Truven Health MarketScan® Research Databases.1 
Enrollees in MarketScan include employees insured by employer-sponsored plans and their dependents 
and Medicare-eligible retirees with employer-provided Medicare Supplemental Plans. The claims data 
contain patient demographic information, enrollment status, health care expenditures, and detailed 
inpatient and outpatient services. Data also include detailed prescription medication information, 
diagnosis codes, and procedures codes. The diagnosis codes are based on the International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), and the procedure codes were 
based on ICD-9-CM, Current Procedural Terminology (CPT®) and Health care Common Procedure 
Coding System (HCPCS). Our data were obtained through the Cecil G. Sheps Center for Health Services 
Research at the University of North Carolina at Chapel Hill. The study was reviewed and approved by the 
University of North Carolina at Chapel Hill Institutional Review Board (IRB).    
SAMPLE AND ELIGIBILITY 
Patient claims were captured between years 2000 and 2013. The sample included all patients 
age 18 and over who were enrolled for at least 6 months before and after their first diagnosis of 
compensated cirrhosis (Aim 1) or their first dual diagnosis of compensated cirrhosis and diabetes (Aims 2 
and 3). The first dual diagnosis date of compensated cirrhosis and diabetes in Aims 2 and 3 was defined 
as either the first date of compensated cirrhosis after a diagnosis of diabetes, or vice versa. Both 
compensated cirrhosis and diabetes were identified using the ICD-9-CM from the Outpatient Services 
Tables and Inpatient Admissions Tables. Compensated cirrhosis was defined as alcoholic cirrhosis of the 
liver (ICD-9-CM code: 571.2), cirrhosis (ICD-9-CM code: 571.5), and biliary cirrhosis (ICD-9-CM code: 
571.6).2 Diabetes was defined as either: 1) more than 2 different dates of service for a diabetic-related 
diagnosis (ICD-9-CM code: 250.xx) from the Outpatient Services Table or 2) more than 1 inpatient 
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encounter with a diagnosis of diabetes3 prior to any decompensation event. Decompensation events 
include ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, 
hepatocellular carcinoma, and acute renal failure. Patients who were diagnosed with any decompensation 
event prior to the first diagnosis of compensated cirrhosis/first dual diagnosis of compensated cirrhosis 
and diabetes were excluded. In addition, to avoid misclassification, patients who were prescribed an 
encephalopathy medication (Lactulose and Rifaxamin), had a diagnosis of HIV (ICD-9-CM code: 042.xx-
044.xx), or had a liver transplant (ICD-9-CM code: V42.7, ICD-9 procedure: 50.5, or CPT code: 47135, 
47136) prior to the first diagnosis of compensated cirrhosis/first dual diagnosis of compensated cirrhosis 
and diabetes were also excluded. To avoid immortal time bias,4 patients who had a first diagnosis of 
diabetes after the first diagnosis of cirrhosis were also excluded in Aim 1. The end of the study period was 
defined as: 1) the first disenrollment; 2) the date of a serious complication (i.e. decompensation event, 
hepatocellular carcinoma, or acute renal failure); or 3) the end of the observation period (December 31, 
2013).   
KEY VARIABLE AND MEASURES 
Patient-level variables were identified from the MarketScan® Commercial Claims and Encounters 
and Medicare Supplemental Databases. Area-level variables were linked from the Dartmouth Atlas and 
the U.S. Census Bureau (Table 2.1).   
Decompensation events (Aims 1 and 3) 
Decompensation events were defined using previously published ICD-9-CM codes:5,6 ascites 
(ICD-9-CM code: 789.59), spontaneous bacterial peritonitis (ICD-9-CM code: 567.23), variceal bleeding 
(ICD-9-CM code: 456.00, 456.10, 456.20, 456.21), hepatic encephalopathy (ICD-9-CM code: 572.20, 
070.2x, 070.40, 070.44, 070.49, 070.60), hepatocellular carcinoma (ICD-9 code: 155)7,8, and acute renal 
failure (ICD-9 code: 584)9,10 (Table 2.2). Patients who filled prescriptions for encephalopathy medications 
(Lactulose and Rifaxamin) were also defined as having hepatic encephalopathy. Patients in the study 
sample were identified as having a decompensation event when they: 1) had at least two diagnoses of 
decompensated cirrhosis from the Outpatient Services Table; 2) had at least one diagnosis of 
decompensated cirrhosis from the Inpatient Services Table;5 3) had at least one diagnosis of acute renal 
failure or hepatocellular carcinoma from either the Outpatient Services Table or Inpatient Services Table; 
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or 4) had been filled with prescribed an encephalopathy medication from the Outpatient Services Table. 
Time-to-decompensation event was defined as the time from first diagnosis of cirrhosis to the first 
diagnosis of decompensation event. The censoring date was defined as either the first drop-out date or 
the end of the study period (December 31, 2013).  
Diabetes severity proxy (Aims 1 and 3) 
Diabetic patients were categorized into four categories in Aim 1 as a proxy of severity: 1) diet 
controlled (without any diabetic medication); 2) oral agents; 3) injectable agents (including insulin and 
non-insulin injectable agents); and 4) both oral and injectable agents (Table 2.3). To avoid immortal time 
bias4, patients who had a first diagnosis of diabetes after the first diagnosis of cirrhosis were excluded. 
The diet control group was the reference group.  
In Aim 3, diabetic medications were measured in the 6 months prior to the first dual diagnosis. 
Patients were not considered to have diabetes if they had diagnosis of diabetes later than the diagnosis of 
compensated cirrhosis (i.e., no diabetes diagnosis 6 months prior to the first dual diagnosis date). 
Patients were considered as having diabetes with diet control if they had diagnosis of diabetes prior to 
diagnosis of compensated cirrhosis but did not use any diabetic medication during the observed 6 
months. Patients who had diabetes diagnosis prior to the first compensated cirrhosis diagnosis and were 
prescribed diabetic medications were categorized as diabetic medication with oral agents only, injectable 
agents only, and both oral and injectable agents, based on the listed medications. Therefore, five 
categories of proxy for patients’ severity of diabetes were: 1) no diabetes; 2) diabetes with diet control; 3) 
diabetes with oral agents only; 4) diabetes with injectable agents only; and 5) diabetes with both oral and 
injectable agents. No diabetes served as the reference group. 
Physician specialty (Aim 2) 
Physician specialty was identified based on “Provider Type (STDPROV)” from the MarketScan 
data Outpatient Services Table. According to the MarketScan data dictionary,11 106 different physician 
specialties (STDPROV between 200 and 460, not including surgeons), were listed in the outpatient files. 
Among them, gastroenterologist (GI) were defined as physicians in gastroenterology (STDPROV = 275) 
and endocrinologist (ENDO) were defined as physicians in endocrinology and metabolism (STDPROV = 
270). Because there was no category for primary care provider (PCP), we used a definition based on 
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previous studies:12–15 medical doctor not elsewhere classified (NEC), internal medicine NEC, family 
practice, geriatric medicine, obstetrics/gynecology, and multi-specialty group practice (STDPROV = 200, 
204, 240, 320, 245, and 206 respectively). Physician encounters were also summed by specialty in each 
year from 2000 to 2013. 
Physician mix categories (Aims 2 and 3) 
Dually-diagnosed patients may encounter multiple health conditions that require care from 
different physician specialties. Therefore, these patients were categorized into four physician mix 
categories based on the physicians specialties mentioned above: 1) PCP with no GI/ENDO, 2) GI/ENDO 
with no PCP, 3) both PCP and GI/ENDO, and 4) neither PCP nor GI/ENDO. PCP with no GI/ENDO was 
the reference group in the regression analysis.  
Physician density (Aims 2 and 3) 
Physician density measures access to each physician specialty among dually diagnosed patients 
with compensated cirrhosis and diabetes. Three physician densities were included: density of PCP, 
density of GI/ENDO, and density of other physicians. These three densities were linked from the 
Dartmouth Atlas of Health Care (www.dartmouthatlas.org) to MarketScan data using Federal Information 
Processing Standard (FIPS) county code and metropolitan statistical area (MSA) code. MarketScan data 
contain enrollees’ five-digit FIPS code between year 2000 and 2010, but the variable was then dropped 
due to privacy concerns. For patients who had their first dual-diagnosis of compensated cirrhosis and 
diabetes in 2011 and later, MSA was used to identify patients’ geographic location. MSA identifies 
whether patients resided in a metropolitan area, including the state and county name. Patients who 
resided in non-metropolitan areas after 2011 did not have county and state information and were 
dropped. The five-digit FIPS codes (2000 to 2010) and the state and county (linked through MSA, 2011-
2013) were linked with hospital referral regions (HRRs) through the Dartmouth Atlas Project. The 
Dartmouth Atlas Project identified 306 HRRs based on how Medicare patients were admitted to tertiary 
care for major cardiovascular surgeries.16 Physician density per 100,000 residents in each HRR, including 
PCP, GI, ENDO, and other specialties were available in 1996, 2006, and 2011. To obtain the most 
relevant physician density for each year in our study, we linked the physician density with the closest 
time. Hence, years 2000 and 2001 were linked with physician density in 1996; years 2002 through 2008 
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were linked with physician density in 2006; and years 2009 through 2013 were linked with physician 
density in 2011. If multiple HRRs were linked to a single patient, weighted physician density based on the 
total population in each HRR was calculated. Physician densities served as control variables in Aim 2 and 
as instrumental variables in Aim 3. 
Health Care Utilization (Aim 2) 
Annual physician visits and annual health care expenditures by each patient were observed from 
the MarketScan Outpatient Services Table. Physician visits were summed by each visit for each physician 
mix category during the observation period. Total health care expenditures were the gross covered 
payments, which were the sum of deductible, coinsurance, coordination of benefits and other savings, 
and net payments from each outpatient visit. Average physician visits and health care expenditures per 
patient per year were also reported. 
All-cause hospitalization (Aim 3) 
Inpatient admissions occurring after the first dual diagnosis with compensated cirrhosis and 
diabetes were treated as an indication of poor care management. Using the Inpatient Admission 
Information Table, we created an indicator for any hospitalization throughout the study period. For brevity, 
we sometimes refer to all-cause hospitalization as “hospitalization.”  
Other control variables (All 3 aims) 
Demographic variables were identified through the Annual Enrollment Summary Table and 
included age, gender, and geographic region (Table 2.1). The Elixhauser Comorbidities index was used 
to measure health status.17,18 Two major comorbidity indices are widely used in the literature: Charlson 
Comorbidity Index19 and Elixhauser Comorbidity Index20. Previous studies have found that the Elixhauser 
Comorbidity Index outperformed the Charlson index in summarizing disease burden and predicting in-
hospital mortality.17,18 Although mortality is not an outcome of this study, decompensation events require 
hospitalization and are highly related to mortality among patients with cirrhosis.21 Moreover, Quan and 
colleagues updated Elixhauser Comorbidity Index with enhanced coding algorithm;22 therefore, we used 
the enhanced Elixhauser Comorbidity Index as a health status proxy in this study. It was defined between 
six months prior to the first cirrhosis diagnosis date and the first cirrhosis diagnosis/dual-diagnosis date. 
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To avoid collinearity, diseases related to liver disease and diabetes in the Elixhauser Comorbidity Index 
were excluded. The remaining 28 comorbidities were summed (0-28) (Table 2.4).   
Although socioeconomic status (SES) was not available in the database, area-level median 
income was used as a proxy estimation of patients’ SES. Area-level median income was linked through 
five-digit FIPS code (2000 through 2010) and MSA (2011 through 2013). In addition, disease-related 
medications23–27 were also controlled in the analysis in Aims 1 and 3 (Table 2.4). 
ANALYTIC APPROACH 
The unit of analysis was the patient (Table 2.5). All analyses were conducted using SAS for 
Windows, Version 9.4 (SAS Institute Inc, Cary, NC, USA) and STATA 13.0 (STATA Corp, College 
Station, TX, USA). The power calculation for each aim was set at the 80% level. P-values of < 0.05 were 
considered statistically significant.  
Aim 1: To determine whether patients diagnosed with cirrhosis and diabetes are more likely to 
experience a decompensation event than patients diagnosed only with cirrhosis. Logistic regression was 
used to compare the odds of developing a decompensation event among dually diagnosed patients vs. 
patients who were only diagnosed with cirrhosis. Age, gender, area-level median income, geographic 
location, number of comorbidities, and disease-related medication use were used as the control variables.  
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The key dependent variable (Y) is any decompensation event, including ascites, spontaneous 
bacterial peritonitis, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, and acute renal 
failure. The β’s represent the predisposing, enabling, and need characteristics described in Table 2.1. 
The null hypothesis is that patients who were dually diagnosed with cirrhosis and diabetes have the same 
odds of a developing decompensation event as those who were diagnosed with only compensated 
cirrhosis. The chi-square test was used for unadjusted comparisons between patients with compensated 
cirrhosis only and dually-diagnosed patients. Therefore, if the chi-square test was statistically significant, 
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the result indicates that there is a statistically significant different between the two groups (i.e., patients 
with compensated cirrhosis only versus dually-diagnosed patients).  
Cox proportional hazard models and Kaplan-Meier plots were used to consider time-to-
decompensation event.  
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Patients who discontinued enrollment in the system or developed any decompensation event 
after the first diagnosis date of cirrhosis were censored. Covariates were the same as in the logistic 
regression. The null hypothesis for survival analysis is that there is no difference in time-to- 
decompensation event between the two groups. The chi-square test was used to test unadjusted 
comparisons between the two groups. If chi-square test is statistically significant the result indicates that 
there is a statistically significant difference of time-to-decompensation event between the two groups. 
Adjusted odds ratios (ORs), hazard ratios (HRs) and confidence intervals (CI) were reported based on 
logistic regression and Cox proportional hazard models.    
Power Analysis for Aim 1. Approximately 40% of patients with cirrhosis also had a diabetes 
diagnosis.28  Among these patients, about 36%-58% of them then developed decompensation events.29,30 
Therefore, assuming this prevalence, effect size, 80% power and an alpha of .05, the required sample 
size for a two-sample comparison is 713 patients per group (sampsi .4 .475, power(.8)). Hence, the 
sample size requirement for Aim 1 was 1,426 patients with compensated cirrhosis.  
Aim 2: To determine what physician specialties are treating patients dually diagnosed with 
compensated cirrhosis and diabetes. Hypothesis: Regardless of the complexity of their health condition, 
there is still a large group of patients who receive care from PCP only. We first examined patient 
characteristics, the distribution of visits to physician mix categories, and the number of physician 
encounters between 2000 and 2013. We then compared the percentage and average number of annual 
visits to each physician specialty by physician mix category. Time trends of the percentage and the 
number of visits for physician mix categories were analyzed. Furthermore, to understand the 
characteristics that affect patients’ physician mix, a multinomial probit model was estimated to compare 
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the odds of visiting different physician mix categories, controlling for age, gender, geographic location, 
physician density, number of comorbidities, and area-level median income.  
ܲݎ݋ܾ൫ ௝ܻหܺூ൯ ൌ 	ߙ ൅ ߚଵ௝ ∗ ݄ܲݕݏ݅ܿ݅ܽ݊	݀݁݊ݏ݅ݐ݅݁ݏ ൅ ߚଶ௝ ∗ ܨ݈݁݉ܽ݁ ൅ ߚଷ௝ ∗ ܣ݃݁ ൅ ߚସ௝ ∗ ܴ݁݃݅݋݊ ൅ ߚହ௝
∗ ܥ݋݉݋ݎܾ݅݀݅ݐ݅݁ݏ ൅ ߚ଺௝ ∗ ܯ݁݀݅ܽ݊	݅݊ܿ݋݉݁ ൅ ߝ 
The key dependent variable Yj is physician mix category. Marginal effects on the probability of 
visiting each physician mix category and CIs were calculated and reported based on the delta method. 
Aim 2 is purely descriptive with no hypotheses to test. 
Aim 3: To determine whether receiving care from either PCP or GI/ENDO only for dually 
diagnosed patients with cirrhosis and diabetes result in a higher likelihood of experiencing a 
decompensation event and/or all-cause hospitalization when compared with dually diagnosed patients 
who were treated by both PCP and GI/ENDO. Hypothesis: Patients who were treated by either PCP or 
GI/ENDO only will have higher likelihood of experiencing a decompensation event and/or all-cause 
hospitalization compared to those who were treated by mix of these specialists. We first examined patient 
characteristics and the distribution of any decompensation event and/or hospitalization between 2000 and 
2013. We then assessed the effect of physician mix on the development of clinical decompensation event 
and all-cause hospitalization among dually-diagnosed patients. To avoid selection bias and control for the 
endogeneity of patients’ physician mix categories, instrumental variables using two-stage residual 
inclusion (2SRI) were used.31 A multinomial probit model was used as the first stage of 2SRI to compare 
the odds of visiting different physician mix categories, controlling for age, gender, geographic location, 
number of comorbidities, area-level median income, and medications.  
1ݏݐ	ݏݐܽ݃݁: ܲݎ݋ܾ൫ ௝ܻห ௜ܲ൯
ൌ 	ߙ ൅ ߜ௝ ∗ ݄ܲݕݏ݅ܿ݅ܽ݊	݀݁݊ݏ݅ݐ݅݁ݏ ൅ ߚଵ௝ ∗ ܨ݈݁݉ܽ݁ ൅ ߚଶ௝ ∗ ܣ݃݁ ൅ ߚଷ௝ ∗ 	ܴ݁݃݅݋݊ ൅ ߚସ௝
∗ ܥ݋݉݋ݎܾ݅݀݅ݐ݅݁ݏ ൅ ߚହ௝ ∗ ܯ݁݀݅ܽ݊	݅݊ܿ݋݉݁ ൅ ߚ଺௝ ∗ ܦܾ݅ܽ݁ݐ݅ܿ	ݏ݁ݒ݁ݎ݅ݐݕ ൅ ߚ଻௝
∗ ܱݐ݄݁ݎ	݉݁݀݅ܿܽݐ݅݋݊ ൅ ߝ	 
Pi indicated four physician mix categories. Physician density was the instrumental variable (i.e., 
included in the first stage but excluded from the second stage outcome equation). Marginal effects and 
CIs on the probability of visiting each physician mix category were calculated and reported based on the 
delta method. In addition, the strength of the instruments was tested using a F-test of the joint significance 
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of the coefficients for the three physician density instruments. Standardized residuals were calculated 
from the first stage32,33 and were included in the second stage logistic regression for the probability of any 
decompensation event and hospitalization.  
ܵݐܽ݊݀ܽݎ݀݅ݖ݁݀	ݎ݁ݏ݅݀ݑ݈ܽݏ:	ݍప	ෞ ൌ 	ܲݎ෢൫ݕ௜௝หݖ௜൯ି
ଵ
ଶ ∗ ቀ1 െ	ܲݎ෢൫ݕ௜௝หݖ௜൯ቁ
ିଵଶ ∗ 	ቀ1 െ	ܲݎ෢൫ݕ௜௝หݖ௜൯ቁ 
2݊݀	ܵݐܽ݃݁:	ܲݎ݋ܾሺܻ|ܺሻ ൌ 	 11 ൅ ݁ି௑ఉ		
ݓ݄݁ݎ݁	ܺߚ ൌ 	ߙ ൅ ߜ ∗ ݄ܲݕݏ݅ܿ݅ܽ݊	݉݅ݔ	݀ݑ݉݉݅݁ݏ ൅ ߚଵ ∗ ܨ݈݁݉ܽ݁ ൅ ߚଶ ∗ ܣ݃݁ ൅ ߚଷ ∗ ܴ݁݃݅݋݊ ൅ ߚସ
∗ ܥ݋݉݋ݎܾ݅݀݅ݐ݅݁ݏ ൅ ߚହ ∗ ܯ݁݀݅ܽ݊	݅݊ܿ݋݉݁ ൅ ߚ଺ ∗ ܦܾ݅ܽ݁ݐ݅ܿ	ݏ݁ݒ݁ݎ݅ݐݕ	݌ݎ݋ݔݕ ൅ ߚ଻
∗ ܱݐ݄݁ݎ	ܿ݋݊ݐݎ݋݈݈݁݀	݉݁݀݅ܿܽݐ݅݋݊ ൅ ߛ ∗ ܴ݁ݏ݅݀ݑ݈ܽݏ	݂ݎ݋݉	1ݏݐ	ݏݐܽ݃݁ ൅ ߝ 
Zi = [Xi wi], where wi indicated instrumental variables that satisfy all the assumptions. The key 
dependent variable Y for the second stage is all-cause hospitalization and/or any decompensation event, 
including ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, 
hepatocellular carcinoma, and acute renal failure. Adjusted odds ratios (ORs) and 95% CIs were reported 
based on the second stage logistic regression after bootstrapping. Endogeneity of physician mix in the 
outcome equation was tested using a F-test of the joint significance of the coefficients of the standardized 
residuals. Results of regular logistic regression and 2SRI on each decompensation event and all-cause 
hospitalization on physician densities were also compared. 
Power Analysis for Aim 3. There have been several studies on physician mix visited in the past 
seven years, focusing mainly on cancer patients.12–15 These studies found that approximately 34% of 
patients visited a PCP but not an oncologist, while about 46% visited both a PCP and an oncologist.  
Therefore, if we assume the same distribution of physicians seen, we can estimate that about 40% of 
patients will see a PCP, GI, and/or ENDO.  Based on preventive screening received among cancer 
patients34, we assume the screening prevalence (35%) is the same as the percentage of patients with 
improved outcome due to visiting multiple specialties. Therefore, with the estimated prevalence, effect 
size, 80% power and an alpha of .05, the required sample size of a two-sample comparison is 1,511 
patients per group (sampsi .4 .35, power(.8)). Hence, 3,022 patients who were dually diagnosed with 
compensated cirrhotic and diabetes were needed for Aims 2 and 3. 
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Table 2.1 - Key variables and measurements 
Factors Affecting Health Care Use Variable Type Value Description 
Predisposing   
Age  Categorical 1 - Under 40 
2 - 40-44 
3 - 45-49 
4 - 50-54 
5 - 55-59 
6 - 60-64 
7 - 65+ 
 
Gender Binary 0 - Male 
1 - Female 
Area-level median income Continuous 0 - 999,999 
Enabling   
Physician mix categories Categorical 1 - PCP with no GI/ENDO 
2 - GI/ENDO with no PCP 
3 - Both PCP and GI/ENDO 
4 - Neither PCP nor GI/ENDO 
Physician density per 100,000 
population by FIPS code/MSA 
Continuous 0 - 999,999 
Geographic location Categorical 1 - Northeast  
2 - Midwest 
3 - South 
4 - West 
MSA Binary 0 - Non-MSA 
1 - MSA 
Need   
Elixhauser Comorbidity Index Continuous 0 - 28 
Diabetes severity proxy  Categorical (Aim 1) 
1 - Diabetes with diet controlled 
(without any diabetic medication) 
2 - Oral agents 
3 - Injectable agents (including 
insulin and non-insulin injectable 
agents) 
4 - Both oral and injectable agents. 
 
(Aim 3) 
1 - No diabetes prior to cirrhosis 
diagnosis 
2 - Diabetes with diet controlled  
3 - Oral agents 
4 - Injectable agents  
5 - Both oral and injectable agents. 
 
 25 
Factors Affecting Health Care Use Variable Type Value Description 
Medications   
Diabetes oral medication Binary 0 - No use of oral medication 
1 - Use of oral medication 
Insulin Binary 0 - No use of insulin 
1 - Use of insulin 
Statin Binary 0 - No use of statin 
1 - Use of statin 
ACEI Binary 0 - No use of ACEI 
1 - Use of ACEI 
ARB Binary 0 - No use of ARB 
1 - Use of ARB 
SBB Binary 0 - No use of SBB 
1 - Use of SBB 
NSBB Binary 0 - No use of NSBB 
1 - Use of NSBB 
Health Outcome   
Decompensation events Binary 0 - No decompensation event 
1 - Has decompensation event 
Ascites Binary 0 - No ascites 
1 - Has ascites 
Spontaneous bacterial peritonitis Binary 0 - No spontaneous bacterial 
peritonitis 
1 - Has spontaneous bacterial 
peritonitis 
Variceal bleeding Binary 0 - No variceal bleeding 
1 - Has variceal bleeding 
Hepatic encephalopathy Binary 0 - No hepatic encephalopathy 
1 - Has hepatic encephalopathy 
Hepatocellular carcinoma Binary 0 - No hepatocellular carcinoma 
1 - Has hepatocellular carcinoma 
Acute renal failure Binary 0 - No acute renal failure 
1 - Has acute renal failure 
All-cause hospitalization Binary 0 - No hospitalization 
1 - Has hospitalization 
Total physician visits Continuous 0 - 999 
Total health care expenditures Continuous 0 - 999,999 
FIPS, Federal Information Processing Standard; MSA, metropolitan statistical area; ACEI, angiotensin-
converting enzyme inhibitors; ARB, angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, 
non-selective beta-blocker  
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Table 2.2 - List of ICD-9-CM codes for decompensated cirrhosis5 
Disease ICD-9 Description of the code 
Ascites 789.59 Ascites 
Spontaneous bacterial 
peritonitis 567.23 Spontaneous bacterial peritonitis 
Variceal bleeding 
456.00 Esophageal varices with bleeding 
456.10 Esophageal varices without mention of bleeding 
456.2x Esophageal varices in diseases classified elsewhere 
456.20 Esophageal varices in diseases classified elsewhere with bleeding 
456.21 Esophageal varices in diseases classified elsewhere without bleeding 
Hepatic encephalopathy 
572.20 Hepatic encephalopathy 
070.2x Viral hepatitis B with hepatic coma 
070.22 Viral hepatitis B with hepatic coma—chronic, without mention of hepatitis delta 
070.23 Viral hepatitis B with hepatic coma—chronic, with hepatitis delta
070.40 Other specified viral hepatitis with hepatic coma 
070.44 Chronic hepatitis C with hepatic coma 
070.49 Other specified viral hepatitis with hepatic coma 
070.60 Unspecified viral hepatitis with hepatic coma 
Hepatocellular carcinoma 155.xx Hepatocellular carcinoma 
Acute renal failure 584.xx Acute renal failure 
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Table 2.3 - List of disease-related medications 
Medication Category Generic name 
Cirrhosis-related  
Encephalopathy Lactulose 
 Rifaximin 
Diabetes-related35  
Oral medication  
Sulfonylureas Chlorpropamide 
 Glipizide  
 Glyburide 
 Glimepiride 
Biguanides Metformin 
Meglitinides Repaglinide  
 Nateglinide 
Thiazolidinediones Rosiglitazone 
 Pioglitazone 
DPP-4 Inhibitors Sitagliptin 
 Saxagliptin 
 Linagliptin 
 Alogliptin 
SGLT2 Inhibitors Canagliflozin 
 Dapagliflozin 
 Empagliflozin 
Alpha-glucosidase inhibitors Acarbose 
 Miglitol 
Bile acid sequestrants Colesevelam 
Insulin Insulin 
Injectable medications  
Amylin mimetics Pramlintide 
Incretin mimetics Exenatide 
 Exenatide extended release 
 Liraglutide 
Other controlled medication  
Statins36 Atorvastatin 
 Fluvastatin 
 Lovastatin 
 Pitavastatin 
 Pravastatin 
 Rosuvastatin 
 Simvastatin 
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Medication Category Generic name 
ACEI/ARB37  
ACEI Perindopril erbumine 
 Quinapril hydrochloride 
 Ramipril 
 Captopril 
 Benazepril hydrochloride 
 Trandolapril 
 Lisinopril 
 Trandolapril and verapamil hydrochloride 
 Moexipril hydrochloride 
 Lisinopril 
ARB Candesartan cilexetil 
 Irbesartan 
 Olmesartan medoxomil 
 Losartan potassium 
 Valsartan 
 Azilsartan kamedoxomil 
 Losartan potassium and hydrochlorothiazide 
 Telmisartan 
 Eprosartan mesylate 
 Telmisartan and amlodipine besylate 
NSBB38  Carvedilol  
Nadolol 
Propranolol 
SBB38 Acebutolol 
 Atenolol 
 Betaxolol 
 Bisoprolol 
 Esmolol 
 Labetalol 
 Metoprolol 
 Nebivolol 
 Penbutolol 
 Pindolol 
 Sotalol 
 Timolol 
DPP-4 Inhibitors, dipeptidyl peptidase 4 inhibitors; SGLT2 Inhibitors, sodium/glucose cotransporter 2 
inhibitors; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; SBB, 
selective beta-blocker; NSBB, non-selective beta-blocker
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Table 2.4 - Elixhauser Comorbidity Index (ECI)22 
Comorbidities Elixhauser’s original ICD-9-CM Enhanced ICD-9-CM22 
Congestive heart 
failure 
398.91, 402.11, 402.91, 404.11, 404.13, 
404.91, 404.93, 428.x 
398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4-425.9, 428.x 
Cardiac arrhythmias 
426.10, 426.11, 426.13, 426.2-426.53, 
426.6-426.8, 427.0, 427.2, 427.31, 427.60, 
427.9, 785.0, V45.0, V53.3 
426.0, 426.13, 426.7, 426.9, 426.10, 
426.12, 427.0-427.4, 427.6-427.9, 
785.0, 996.01, 996.04, V45.0, V53.3
Valvular disease 093.2, 394.0-397.1, 424.0-424.91. 746.3-746.6, V42.2, V43.3 
093.2, 394.x-397.x, 424.x, 746.3-
746.6, V42.2, V43.3 
Pulmonary circulation 
Disorders 416.x, 417.9 
415.0, 415.1, 416.x, 417.0, 417.8, 
417.9 
Peripheral vascular 
disorders 
440.x, 441.2, 441.4, 441.7, 441.9, 443.1-
443.9, 447.1, 557.1, 557.9, V43.4 
093.0, 437.3, 440.x, 441.x, 443.1– 
443.9, 447.1, 557.1, 557.9, V43.4 
Hypertension, 
uncomplicated 401.1, 401.9 401.x 
Hypertension, 
complicated 
402.10, 402.90, 404.10, 404.90, 405.1. 
405.9 402.x-405.x 
Paralysis 342.0. 342.1, 342.9-344.x 334.1, 342.x, 343.x, 344.0-344.6, 344.9 
Other neurological 
disorders 
331.9, 332.0, 333.4, 333.5, 334.x, 335.x, 
340.x, 341.1-341.9, 345.0, 345.1, 345.4, 
345.5, 345.8, 345.9. 348.1, 348.3, 780.3, 
784.3 
331.9, 332.0, 332.1, 333.4, 333.5, 
333.92, 334.x-335.x, 336.2, 340.x, 
341.x, 345.x, 348.1, 348.3, 780.3, 
784.3 
Chronic pulmonary 
disease 
490-492.8, 493.00-493.91, 494.x-505.x, 
506.4 
416.8, 416.9, 490.x-505.x, 506.4, 
508.1, 508.8 
Hypothyroidism 243-244.2, 244.8, 244.9 240.9, 243.x, 244.x, 246.1, 246.8 
Renal failure 403.11, 403.91, 404.12, 404.92, 585.x, 586.x, V42.0, V45.1, V56.0, V56.8 
403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 404.13, 404.92, 
404.93, 585.x, 586.x, 588.0, V42.0, 
V45.1, V56.x 
Peptic ulcer disease 
excluding bleeding 
531.70, 531.90, 532.70, 532.90, 533.70, 
533.90, 534.70, 534.90, V12.71 
531.7, 531.9, 532.7, 532.9, 533.7, 
533.9, 534.7, 534.9 
AIDS/HIV 042.x-044.x 042.x-044.x 
Lymphoma 200.x-202.3x, 202.5-203.0, 203.8, 238.6, 273.3, V10.71, V10.72, V10.79 200.x-202.x, 203.0, 238.6 
Metastatic cancer 196.x-199.x 196.x-199.x 
Solid tumor without 
metastasis 
140.x-172.x, 174.x, 175.x, 179.x-195.x, 
V10.x 140.x-172.x, 174.x-195.x 
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Comorbidities Elixhauser’s original ICD-9-CM Enhanced ICD-9-CM22 
Rheumatoid 
arthritis/collagen 
vascular diseases 
701.0, 710.x, 714.x, 720.x, 725.x 
446.x, 701.0, 710.0-710.4, 710.8, 
710.9, 711.2, 714.x, 719.3, 720.x, 
725.x, 728.5, 728.89, 729.30 
Coagulopathy 286.x, 287.1, 287.3-287.5 286.x, 287.1, 287.3-287.5 
Obesity 278.0 278.0 
Weight loss 260.x-263.x 260.x-263.x, 783.2, 799.4 
Fluid and electrolyte 
disorders 276.x 253.6, 276.x 
Blood loss anemia 280.0 280.0 
Deficiency anemia 280.1-281.9, 285.9 280.1-280.9, 281.x 
Alcohol abuse 291.1, 291.2, 291.5‐291.9, 303.9, 305.0, V113 
265.2, 291.1‐291.3, 291.5-291.9, 
303.0, 303.9, 305.0, 357.5, 425.5, 
535.3, 571.0-571.3, 980.x, V11.3 
Medication abuse 292.0, 292.82‐292.89, 292.9, 304.0, 305.2-305.9 292.x, 304.x, 305.2-305.9, V65.42 
Psychoses 295.x-298.x, 299.1 293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x 
Depression 300.4, 301.12, 309.0, 309.1, 311 296.2, 296.3, 296.5, 300.4, 309.x, 311 
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Table 2.5 - Hypotheses, analysis approach, and expected outcome by Aim  
Aims Hypotheses /  Expected Outcome Inclusion Criteria Exclusion Criteria Analysis 
Outcome/ 
Treatment Definition 
1. To determine whether 
patients dually diagnosed with 
compensated cirrhosis and 
diabetes are more likely to 
experience a decompensation 
event than patients diagnosed 
only with compensated 
cirrhosis. 
Patients with both 
cirrhosis and 
diabetes are more 
likely to experience a 
decompensation 
event than patients 
diagnosed only with 
cirrhosis. 
Patients who 
were over 18 
years old and 
diagnosed with 
compensated 
cirrhosis 
Patients who were 
younger than 18 years 
old, diagnosed with 
decompensated cirrhosis, 
acute renal failure, HCC, 
HIV, had a liver 
transplantation, and were 
on any encephalopathy 
medication prior to the 
first compensated 
cirrhosis diagnosis date 
Logistic 
regression  
and survival 
analysis 
Outcome: 
decompensation event 
Treatment group: 
patients dually 
diagnosed with 
compensated cirrhosis 
and diabetes 
Comparison group: 
patients diagnosed with 
cirrhosis only 
2. To determine what 
physician specialties are 
treating patients dually 
diagnosed with compensated 
cirrhosis and diabetes. 
Regardless of the 
complexity of their 
health condition, there 
is still a large group of 
patients who did not 
receive care from both 
PCP and GI/ 
ENDO 
Patients who 
were over 18 
years old and 
dually 
diagnosed with 
compensated 
cirrhosis and 
diabetes 
Patients who were 
younger than 18 years 
old, diagnosed with 
decompensated cirrhosis, 
acute renal failure, HCC, 
HIV, had a liver 
transplantation, and were 
on any encephalopathy 
medication prior to the 
first dually diagnosis date 
Multinomial 
probit 
regression 
Physician mix 
categories: 
1. PCP with no GI/Endo 
2. GI/Endo with no PCP 
3. Both PCP and GI/End
4. Neither PCP nor 
GI/Endo 
Outcome: annual total 
visits and health care 
expenditures 
3. To determine whether 
receiving care from either 
PCP or GI/ENDO only for 
dually diagnosed patients with 
cirrhosis and diabetes results 
in a higher likelihood of 
experiencing a 
decompensation event and/or 
all-cause hospitalization when 
compared with dually 
diagnosed patients were 
treated by both PCP and GI/ 
ENDO. 
Patients who were 
treated by either PCP 
or GI/ENDO only will 
have higher likelihood 
of experiencing a 
decompensation 
event and/or all-
cause hospitalization 
compared to those 
who were treated by 
a combination of 
these specialists 
Same as Aim 2 Same as Aim 2 2-Stage 
residual 
inclusion with 
multinomial 
probit model 
as the first 
stage, and 
logistic 
regression as 
the second 
stage 
Outcome: 
decompensation event 
and/or all-cause 
hospitalization 
Physician mix 
categories: 
1. PCP with no GI/Endo 
2. GI/Endo with no PCP 
3. Both PCP and 
GI/Endo 
4. Neither PCP nor 
GI/Endo 
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CHAPTER 3. DIABETES IS ASSOCIATED WITH CLINICAL DECOMPENSATION EVENTS IN 
PATIENTS WITH CIRRHOSIS 
 
BACKGROUND 
Cirrhosis of the liver is an irreversible chronic disorder that causes a significant global health 
burden.1 In the United States, cirrhosis is the eighth leading cause of death and years of life lost.2 
Additionally, the death rate attributed to cirrhosis increased more than 40% in the past two decades.2 The 
prevalence of cirrhosis is increasing mainly due to the rising incidence of fatty liver disease and aging 
baby boomers with hepatitis C infection.3,4 The number of hepatitis C (HCV)-related cirrhotic patients is 
estimated to double in the next ten years,4–6 and will reach a peak of one million by 20204 while the 
number of patients with non-alcoholic fatty liver disease (NAFLD) is estimated to overtake HCV by 2020.7  
Diabetes co-occurs in 14-70% of patients with cirrhosis.8–10 Previous smaller studies on restricted 
populations suggest the presence of diabetes is a risk factor among patients with compensated cirrhosis 
in terms of long-term survival.11 Moreover, patients dually diagnosed with compensated cirrhosis and 
diabetes have increased incidence of developing decompensated cirrhosis.11–18 However, with few 
exceptions,15–17 these studies were conducted using relatively small samples outside of the United States. 
The U.S. studies either only focused on the correlation between diabetes and hepatocellular carcinoma 
(HCC) among elderly patients with cirrhosis,15 or only contained patients in the Department of Veterans 
Affairs (VA).16,17 With the increasing prevalence of both cirrhosis3 and diabetes,19 the intersection of these 
two diseases will become more common in the near future. As the mortality rate of cirrhosis increased 
among the working-age population in the past decade,20 appropriately managing this group of patients is 
critical. Therefore, this study aims to examine the risk of decompensation among a large, national sample 
of working-aged insured patients dually-diagnosed with compensated cirrhosis and diabetes.  
METHODS 
Data Source  
Data for this study were obtained from MarketScan® Commercial Claims and Encounters and 
Medicare Supplemental Databases 2000 – 2013 (Copyright© 2014 Truven Health Analytics Inc. All Rights 
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Reserved). The Truven Health MarketScan® Research Databases include data from employers and 
health plans.21 These claims data contain patient demographic information, enrollment status, health plan 
type, health care expenditures, and medical information, including inpatient and outpatient services. Data 
also included detailed prescription drug information, diagnosis codes, and procedures codes. The 
diagnosis codes were based on the International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM), and the procedure codes were mainly based on ICD-9-CM, Current Procedural 
Terminology (CPT®) and Health Care Common Procedure Coding System (HCPCS). Due to the data 
structure, these databases only included the employed population and their dependents. The study was 
exempted by University of North Carolina at Chapel Hill Institutional Review Board (IRB). Data were 
obtained from The Cecil G. Sheps Center for Health Services Research at University of North Carolina at 
Chapel Hill. 
Study design, setting, and participants 
This retrospective study included patients 18 years of age and older, who were enrolled for at least 
six months before and after the first diagnosis of cirrhosis. All diseases of interest were identified using 
the ICD-9-CM codes from the Outpatient Services Tables and Inpatient Admissions Tables between 
years 2000 and 2013. Compensated cirrhosis was defined as alcoholic cirrhosis of the liver (ICD-9 code: 
571.2), cirrhosis (ICD-9 code: 571.5), and biliary cirrhosis (ICD-9 code: 571.6).22 
Decompensation events were defined using previously published ICD-9-CM codes:23,24 ascites 
(ICD-9-CM code: 789.59), spontaneous bacterial peritonitis (ICD-9-CM code: 567.23), variceal bleeding 
(ICD-9-CM code: 456.00, 456.10, 456.20, 456.21), and hepatic encephalopathy (ICD-9-CM code: 572.20, 
070.2x, 070.40, 070.44, 070.49, 070.60).23 Patients who filled prescriptions for encephalopathy 
medications (Lactulose and Xifaxan) were also defined as having hepatic encephalopathy. Other 
decompensation events included HCC (ICD-9-CM code: 155.xx),25,26 and acute renal failure (ICD-9-CM 
code: 584.xx).27,28 Medications of interest included diabetic medications (oral agents and injectable 
agents), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), statins, 
selective beta-blocker (SBB), and non-selective beta-blocker (NSBB). Medications were observed 
between 6 months prior to the first diagnosis of cirrhosis and development of decompensation event. All 
these codes were captured from the Outpatient Services, Outpatient Drug Claims, and Inpatient Services 
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Table from the MarketScan® Commercial Claims and Encounters and Medicare Supplemental 
Databases. Patients who were under 18 years of age, or had decompensated cirrhosis diagnosed prior to 
the first diagnosis of compensated cirrhosis were excluded. In addition, to avoid misclassification, patients 
who were prescribed an encephalopathy medication, who had a diagnosis of HIV (ICD-9-CM code: 
042.xx-044.xx), or who had a liver transplantation (ICD-9-CM code: V42.7, ICD-9 procedure: 50.5, or CPT 
code: 47135, 47136) prior to the first compensated cirrhosis diagnosis were also excluded.  
Assessment of diabetes 
Diabetes was defined as either: 1) more than 2 different dates of service for a diabetic-related 
diagnosis (ICD-9-CM code: 250.xx) from the Outpatient Services Table; or 2) more than 1 inpatient 
encounter with a diagnosis of diabetes29 before the decompensation event developed. To avoid immortal 
time bias,30 we excluded patients who had a first diagnosis of diabetes after the first diagnosis of cirrhosis. 
In addition, diabetic patients were categorized into four categories as a proxy of severity: 1) diet controlled 
(without any diabetic medication); 2) oral agents; 3) injectable agents (including insulin and non-insulin 
injectables); and 4) both oral and injectable agents. Diet control group was used as the reference group. 
Figure 3.1 displays the sample selection process based on the inclusion and exclusion criteria. 
Assessment of additional covariates 
Demographic variables were identified through the Annual Enrollment Summary Table and 
included age, gender, and geographic region. The Elixhauser Comorbidities index was used to measure 
health status,31,32 which was defined between 6 months prior to the first cirrhosis diagnosis date and the 
first cirrhosis diagnosis date. To avoid collinearity, diseases related to liver disease and diabetes in the 
Elixhauser Comorbidity Index were excluded. The remaining 28 comorbidities were summed (0-28). 
Although social-economic status (SES) was not available in the database, area-level median income was 
used as a proxy estimation of patients’ SES. Area-level median income was linked through 5-digit Federal 
Information Processing Standards (FIPS) code between 2000 and 2010 and metropolitan statistics area 
(MSA) code between 2011 and 2013. Time-to-decompensation event was defined as the time from first 
diagnosis of cirrhosis to the first diagnosis of decompensation event. Censoring date was defined as 
either the first drop-out date or the end of the study period (December 31, 2013). 
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Statistical analysis 
Logistic regression was used to compare the odds of developing a decompensation event among 
dually diagnosed patients vs. patients who only diagnosed with cirrhosis. Age, gender, area-level median 
income, geographic location, number of comorbidities, and disease-related medication use were used as 
the control variables. Cox proportional hazard models and Kaplan-Meier plots were used to consider time-
to-decompensation event. Patients who discontinued enrollment in the system or developed any 
decompensation event after the first diagnosis date of cirrhosis were censored. Adjusted odds ratios 
(ORs), hazard ratios (HRs) and confidence intervals (CI) were reported based on logistic regression and 
Cox proportional hazard models. Covariates were the same as listed for the logistic regression. P-value < 
0.05 was considered statistically significant. All analyses were conducted using SAS for Windows, 
Version 9.4 (SAS Institute Inc, Cary, NC, USA). 
RESULTS  
Of 72,731 patients with compensated cirrhosis meeting eligibility criteria, 20,477 patients (28.2%) 
were diagnosed with diabetes. Descriptive characteristics of patients with cirrhosis are demonstrated in 
Table 3.1. A decompensation event was observed among 33.3% of patients who were dually diagnosed 
with cirrhosis and diabetes, and only 25.9% among patients with cirrhosis only (P-value < 0.01). The most 
prevalent decompensation events were hepatic encephalopathy and acute renal failure. 
Table 3.2 shows the results for patients with cirrhosis between 2000 and 2013 adjusted for 
gender, age, region, number of comorbidities, area-level median income, and medications. After 
controlling for patient characteristics and medication usage, the odds of developing any decompensation 
event was 1.18 times higher for patients who were dually diagnosed with cirrhosis and diabetes than for 
patients with cirrhosis only (95% C.I. = 1.11-1.25, p-value < 0.01). Patients who were male, older, had 
more comorbidities, and had lower median income had increased risk of developing any decompensation 
event. Among the dually-diagnosed patients, patients who were on any diabetic medication had a higher 
risk of developing decompensation events, compared to those who were only on diet control. Patients 
who were prescribed injectable agents had a higher risk of developing decompensation events than those 
who used oral agents only. 
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In the Cox proportional hazard model, patients who were dually diagnosed with diabetes had a 
1.36 times higher hazard rate (95% C.I. = 1.30-1.43, p-value < 0.01) for decompensation after controlling 
for time-to-event and other covariates (Kaplan-Meier Curve shown in Figure 3.2). Patients who were 
male, older, and had more comorbidities also had increased risk of developing any decompensation 
event. The risk for decompensation after controlling for diabetic and other non-diabetic medications was 
similar to the logistic regression model. The same pattern was found for each individual type of 
decompensation event (Figure 3.3 – Figure 3.8).  
Being dually diagnosed with cirrhosis and diabetes also increased the risk of developing each 
decompensation event after adjusting for covariates and time (Table 3.3). Specifically, the HRs for 
developing ascites, variceal bleeding, and acute renal failure were all greater than 1.5 (HR: 1.73 (95% 
C.I.: 1.51-1.98), 1.71 (95% C.I.: 1.57-1.86), and 1.66 (95% C.I.: 1.56-1.77), respectively, p-value < 0.01) 
among dually diagnosed patients compared to those who only diagnosed with cirrhosis. In addition, the 
HR for developing spontaneous bacterial peritonitis and HCC were all higher than patients diagnosed with 
cirrhosis only. 
DISCUSSION 
This is the first nation-wide US study to assess risk of hepatic decompensation events among 
working-age patients with cirrhosis and diabetes. Consistent with previous research conducted in other 
countries,11–15 this study found an increased risk of developing hepatic decompensation events among 
patients who were dually diagnosed with cirrhosis and diabetes. Our results suggest that diabetic patients 
have an increased risk for each category of hepatic decompensation events and that among diabetic 
patients there appears to be a gradient of risk from diet controlled diabetes to patients on oral medications 
to patients’ injectable medications.  
The prevalence of diabetes among patients with liver diseases in this study is similar to the 
studies conducted outside of the U.S., but slightly lower than another conducted in the U.S.15–17 This is 
because the studies conducted in the U.S. were either using the SEER-Medicare data15 or using VA 
data.16,17 Davila et al. compared HCC patients and controls from the SEER-Medicare data found that 
being diagnosed with diabetes is a risk factor for HCC. However, this study was based on an elderly 
population and focused only on HCC as an outcome 15. El-Serag et al. used VA data and found similar 
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results among (mainly male) veterans.16,17 Our study further provides evidence that diabetes is a risk 
factor for any hepatic decompensation event among all patients with cirrhosis.  
We found diabetes to be a risk factor for each individual type of decompensation event as well. 
After adjustment, the hazard ratio for developing each decompensation event was greater than 1 when 
compared with patients diagnosed with cirrhosis only, except for hepatic encephalopathy. However, when 
we look into the severity of diabetes among the dually-diagnosed group, patients who were on diabetic 
medications had statistically significant higher HRs of developing hepatic encephalopathy than diabetic 
patients who were on diet control.  
Having comorbidities seem to decrease the risk of developing decompensation event when 
comparing between patients with cirrhosis and dually diagnosed with cirrhosis and diabetes. This may 
because when patients suffered from multiple comorbidities, their survival probabilities tend to be lower 
due to competing risks. Thus, the risk for developing liver-related morbidity and mortality also decreases 
due to shorter observation period. 
Consistent with previous studies, our study also found that use of statins and ACEI/ARB 
decreases the hazard of developing portal hypertensive decompensation events for both cirrhosis only 
patients and dually diagnosed patients. Although literature indicates that ACEI/ARB does not retard the 
progression of fibrosis,33 it has been shown to reduce portal pressure among patients with Child Pugh A 
cirrhosis.34 Statins have also been shown to improve outcomes among patients with diabetes,35 as well as 
delaying decompensation events among patients with cirrhosis.36,37 Non-selective beta-blockers seem to 
increase the risk of developing decompensation events. One possible explanation is because we 
captured patients who were diagnosed with esophageal varices, but had not yet bled. These patients then 
received a NSBB prescription as prophylaxis against variceal bleeding. Hence, patients who were using 
NSBB likely already had significant portal hypertension and were at higher risk for any decompensation 
event.  
This study has several implications. As cirrhosis and diabetes become more common there will 
be more overall hepatic decompensation events.  Hepatic decompensation events usually require 
admission to the hospital and frequently to the intensive care unit. These events are expensive and can 
be deadly.  Analysis of diabetes medications used as a surrogate for diabetic control show an gradient of 
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decompensation risk where patients with milder disease (diet controlled) are at less risk for 
decompensation events than patients with more difficult to control disease (those requiring insulin and or 
combination oral/injectable medications).  With this in mind, screening for diabetes among patients with 
cirrhosis may prove to be worthwhile, as might tight regulation of glucose levels among patients already 
diagnosed with diabetes; analogous to diabetes control recommendations that already exist in the care of 
patients with cardiovascular disease.38 Such recommendations would require a prospective randomized 
controlled trial, but this study would seem to provide justification for such an endeavor. 
Several limitations should be noted. First, we could not capture undiagnosed compensated 
cirrhosis or diabetes. Therefore, our results may be under-estimated due to the under-estimated 
prevalence. We addressed this as best we could by using previously published ICD-9-CM codes from the 
literature. Second, MarketScan data lacks information on patients' socioeconomic status, race/ethnicity, 
family history, and lifestyle (e.g. diet, smoking status), which may be important confounders to both 
cirrhosis and diabetes. However, area-level demographics were used as a proxy estimation of SES and 
alcohol abuse is adjusted for as part of the Elixhauser comorbidity index. Third, lab results that measure 
diabetes and cirrhosis are not available. However, we have excluded prevalent decompensation events to 
ensure that we have a well-compensated population of patients with cirrhosis at study entry. Hence, lab 
data are not a necessity in this study. Finally, MarketScan data only contain patients who were insured 
and/or enrolled in Medicare. Since patients who were uninsured or enrolled in Medicaid only may be a 
more vulnerable group and may have higher prevalence of both diabetes and cirrhosis, our results may 
be conservative and underestimate decompensation risk. 
In summary, the number of patients with cirrhosis is growing due to HCV and NAFLD. With 
increases in diabetes incidence in the general population, the number of patients with dual diagnoses of 
cirrhosis and diabetes is also increasing. Our study indicates that patients with cirrhosis and diabetes may 
be at higher risk of having hepatic decompensation events.  Careful management of diabetes in patients 
with liver disease may reduce the risk of hepatic decompensation events in this population.   
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Table 3.1 - Descriptive statistics of patients with cirrhosis, MarketScan 2000-2013 
  Total Cirrhosis only Dually diagnosed with Diabetes P  
  n % n % n % 
Total 72,731  52,254 71.85 20,477 28.15  
Decompensation event 20,359 27.99 13,545 25.92 6,814 33.28 < 0.01
Ascites 2,069 2.84 1,384 2.65 685 3.35 < 0.01
Spontaneous bacterial peritonitis 1,113 1.53 802 1.53 311 1.52 0.87 
Variceal bleeding 6,360 8.74 4,312 8.25 2,048 10.00 < 0.01
Hepatic encephalopathy 10,071 13.85 6,928 13.26 3,143 15.35 < 0.01
Hepatocellular carcinoma 3,629 4.99 2,547 4.87 1,082 5.28 0.02 
Acute renal failure 8,826 12.14 5,368 10.27 3,458 16.89 < 0.01
Female 33,666 46.29 24,348 46.60 9,318 45.50 0.01 
Age group       < 0.01
Under 40 6,210 8.54 5,534 10.59 676 3.30 
40-44 4,902 6.74 4,012 7.68 890 4.35 
45-49 8,885 12.22 7,031 13.46 1,854 9.05 
50-54 13,113 18.03 9,685 18.53 3,428 16.74 
55-59 13,783 18.95 9,463 18.11 4,320 21.10 
60-64 10,156 13.96 6,517 12.47 3,639 17.77 
65+ 15,682 21.56 10,012 19.16 5,670 27.69 
Region       < 0.01
Northeast 11,670 16.05 8,313 15.91 3,357 16.39 
North Central 18,187 25.01 12,938 24.76 5,249 25.63 
South 27,486 37.79 19,389 37.11 8,097 39.54 
West 15,388 21.16 11,614 22.23 3,774 18.43 
Elixhauser Comorbidity Index (mean, SD) 3.19 2.53 1.31 1.42 1.92 1.68 < 0.01
Median income in 10K (mean, SD) 5.11 1.28 5.13 1.28 5.06 1.28 < 0.01
Time to event in year (mean, SD) 2.08 2.11 2.13 2.16 1.96 1.97 < 0.01
Diabetes medication      < 0.01
Diet control 60,098 82.63 52,254 100.00 7,844 38.31 
Oral agents only 6,230 8.57 0 0.00 6,230 30.42 
Injectable agents only 2,017 2.77 0 0.00 2,017 9.85 
Oral and injectable agents 4,386 6.03 0 0.00 4,386 21.42 
Other controlled medication 
ACEI 14,633 20.12 7,689 14.71 6,944 33.91 < 0.01
ARB 8,302 11.41 4,388 8.40 3,914 19.11 < 0.01
Statin 12,695 17.45 6,394 12.24 6,301 30.77 < 0.01
SBB 14,225 19.56 8,907 17.05 5,318 25.97 < 0.01
NSBB 8,912 12.25 5,651 10.81 3,261 15.93 < 0.01
SD, standard deviation; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor 
blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker.  
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Table 3.2 - Logistic regression and Cox proportional hazard model on decompensation event among 
patients with cirrhosis  
 
Logistic regression  Cox proportional hazard model
OR 95% C.I. P-value   HR 95% C.I. P-value 
Dually diagnosed with diabetes 1.18 (1.11 -1.25 ) < 0.01  1.36 (1.30-1.43) < 0.01
Female 0.65 (0.63 -0.68 ) < 0.01  0.68 (0.67-0.70) < 0.01
Age group      
Under 40 - - -  - - - 
40-44 1.83 (1.65 -2.02 ) < 0.01  1.65 (1.51-1.81) < 0.01
45-49 2.16 (1.98 -2.36 ) < 0.01  1.95 (1.80-2.11) < 0.01
50-54 2.48 (2.28 -2.70 ) < 0.01  2.19 (2.03-2.36) < 0.01
55-59 2.83 (2.60 -3.07 ) < 0.01  2.52 (2.34-2.72) < 0.01
60-64 2.61 (2.39 -2.85 ) < 0.01  2.65 (2.45-2.87) < 0.01
65+ 3.65 (3.36 -3.98 ) < 0.01  3.38 (3.14-3.65) < 0.01
Region      
Northeast - - -  - - - 
Midwest 1.22 (1.15 -1.29 ) < 0.01  1.09 (1.04-1.14) < 0.01
South 1.18 (1.11 -1.24 ) < 0.01  1.12 (1.07-1.17) < 0.01
West 1.10 (1.03 -1.16 ) < 0.01  1.03 (0.98-1.08) 0.21
Number of Comorbidities 0.96 (0.96 -0.97 ) < 0.01  0.91 (0.91-0.92) < 0.01
Median Income 0.97 (0.95 -0.98 ) < 0.01  1.01 (0.99-1.02) 0.42
Diabetes medication usage      
Diet control - - -  - - - 
Oral agents only 1.35 (1.24 -1.46 ) < 0.01  1.15 (1.08-1.23) < 0.01
Injectable agents only 1.84 (1.65 -2.05 ) < 0.01  1.55 (1.43-1.69) < 0.01
Oral and injectable agents 1.49 (1.36 -1.63 ) < 0.01  1.15 (1.07-1.24) < 0.01
Other controlled medication      
ACEI*cirrhosis only 0.90 (0.85 -0.96 ) < 0.01  0.85 (0.81-0.90) < 0.01
ACEI*dual diagnosis 0.95 (0.87 -1.05 ) 0.31  0.80 (0.76-0.85) < 0.01
ARB*cirrhosis only 0.90 (0.84 -0.98 ) < 0.01  0.81 (0.76-0.87) < 0.01
ARB*dual diagnosis 0.98 (0.88 -1.10 ) 0.79  0.82 (0.77-0.88) < 0.01
Statin*cirrhosis only 0.48 (0.45 -0.52 ) < 0.01  0.48 (0.45-0.51) < 0.01
Statin*dual diagnosis 1.27 (1.15 -1.41 ) < 0.01  0.63 (0.60-0.67) < 0.01
SBB*cirrhosis only 1.23 (1.16 -1.30 ) < 0.01  1.10 (1.05-1.16) < 0.01
SBB*dual diagnosis 0.99 (0.90 -1.09 ) 0.85  1.13 (1.06-1.19) < 0.01
NSBB*cirrhosis only 3.05 (2.88 -3.23 ) < 0.01  2.14 (2.05-2.23) < 0.01
NSBB*dual diagnosis 0.67 (0.61 -0.75 ) < 0.01  1.55 (1.46-1.64) < 0.01
OR, odds ratio; 95% C.I., 95% confidence interval; HR, hazard ratio; ACEI, angiotensin-converting 
enzyme inhibitors; ARB, angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective 
beta-blocker. 
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Table 3.3 - Cox proportional hazard model among patients with cirrhosis by decompensation event 
  Ascites   
Spontaneous bacterial 
peritonitis   Variceal bleeding 
HR 95% C.I.   HR 95% C.I.   HR 95% C.I. 
Dually diagnosed with diabetes 1.73 (1.51-1.98)***  1.47 (1.19-1.80)***  1.71 (1.57-1.86)*** 
Female 0.46 (0.42-0.51)***  0.55 (0.49-0.63)***  0.66 (0.63-0.69)*** 
Age group         
Under 40 - -  - -  - - 
40-44 1.84 (1.38-2.47)***  1.65 (1.17-2.31)**  1.58 (1.37-1.83)*** 
45-49 2.21 (1.71-2.86)***  2.12 (1.58-2.85)***  1.79 (1.58-2.04)*** 
50-54 2.90 (2.27-3.70)***  2.23 (1.68-2.95)***  2.03 (1.80-2.29)*** 
55-59 3.45 (2.71-4.40)***  2.25 (1.70-2.99)***  2.33 (2.07-2.63)*** 
60-64 3.04 (2.36-3.92)***  1.92 (1.41-2.61)***  2.27 (2.00-2.57)*** 
65+ 2.95 (2.30-3.79)***  1.74 (1.28-2.35)***  2.26 (1.99-2.56)*** 
Region         
Northeast - -  - -  - - 
Midwest 1.03 (0.89-1.19)  1.09 (0.90-1.33)  1.12 (1.03-1.22)** 
South 1.20 (1.04-1.37)***  1.10 (0.91-1.33)  1.21 (1.11-1.31)*** 
West 0.94 (0.81-1.09)  1.10 (0.90-1.34)  1.08 (0.99-1.18) 
Number of Comorbidities 0.93 (0.92-0.95)***  0.89 (0.86-0.91)***  0.82 (0.81-0.83)*** 
Median Income 1.11 (1.08-1.15)***  1.09 (1.04-1.15)***  1.04 (1.02-1.06)*** 
DM medication usage         
Diet control - -  - -  - - 
Oral agents only 0.85 (0.69-1.04)  0.95 (0.70-1.29)  1.16 (1.03-1.30)* 
Injectable agents only 1.17 (0.90-1.52)  1.28 (0.87-1.88)  1.00 (0.84-1.18) 
Oral and injectable agents 0.81 (0.64-1.03)  0.98 (0.70-1.39)  1.07 (0.94-1.23) 
Other controlled medication         
ACEI*cirrhosis only 0.62 (0.51-0.74)***  0.70 (0.55-0.88)**  0.69 (0.62-0.76)*** 
ACEI*dual diagnosis 0.86 (0.71-1.03)  0.70 (0.53-0.92)*  0.69 (0.62-0.77)*** 
ARB*cirrhosis only 0.81 (0.66-1.00)  0.70 (0.52-0.96)*  0.70 (0.62-0.80)*** 
ARB*dual diagnosis 0.75 (0.60-0.94)*  0.61 (0.43-0.86)**  0.74 (0.65-0.83)*** 
Statin*cirrhosis only 0.32 (0.25-0.41)***  0.23 (0.15-0.33)***  0.33 (0.29-0.38)*** 
Statin*dual diagnosis 0.50 (0.41-0.61)***  0.45 (0.33-0.62)***  0.60 (0.53-0.67)*** 
SBB*cirrhosis only 0.91 (0.78-1.07)  1.11 (0.91-1.37)  0.84 (0.76-0.93)*** 
SBB*dual diagnosis 0.90 (0.74-1.10)  1.14 (0.85-1.52)  0.90 (0.80-1.01) 
NSBB*cirrhosis only 1.89 (1.65-2.17)***  1.95 (1.62-2.34)***  3.33 (3.11-3.57)*** 
NSBB*dual diagnosis 1.71 (1.42-2.06)***  2.02 (1.54-2.65)***  2.48 (2.24-2.74)*** 
*P < 0.05; **P < 0.01; ***P < 0.001. HR, hazard ratio; C.I., confidence interval; P, P-value; ACEI, angiotensin-converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker. 
 
 
 
 
45 
Table 3.3 - Cox proportional hazard model among patients with cirrhosis by decompensation event (Cont.) 
  Hepatic encephalopathy   Hepatocellular carcinoma   Acute renal failure HR 95% C.I.   HR 95% C.I.   HR 95% C.I. 
Dually diagnosed with diabetes 0.89 (0.82-0.97)**  1.27 (1.13-1.42)***  1.66 (1.56-1.77) 
Female 0.73 (0.70-0.76)***  0.43 (0.40-0.46)***  0.66 (0.63-0.69) 
Age group         
Under 40 - -  - -  - - 
40-44 1.89 (1.65-2.16)***  1.54 (1.20-1.98)***  1.47 (1.26-1.70)*** 
45-49 2.49 (2.21-2.79)***  2.72 (2.21-3.35)***  1.74 (1.53-1.99)*** 
50-54 2.64 (2.36-2.95)***  3.58 (2.94-4.36)***  2.01 (1.78-2.28)*** 
55-59 2.95 (2.64-3.30)***  4.16 (3.42-5.06)***  2.46 (2.18-2.77)*** 
60-64 2.87 (2.56-3.23)***  4.10 (3.34-5.03)***  2.60 (2.29-2.94)*** 
65+ 3.53 (3.16-3.96)***  4.53 (3.70-5.53)***  3.65 (3.24-4.12)*** 
Region         
Northeast - -  - -  - - 
Midwest 1.17 (1.09-1.26)***  0.85 (0.77-0.94)**  1.21 (1.12-1.29)*** 
South 1.29 (1.21-1.39)***  0.85 (0.77-0.94)**  1.11 (1.04-1.19)** 
West 1.28 (1.19-1.37)***  0.90 (0.81-1.00)*  0.91 (0.84-0.98)* 
Number of Comorbidities 0.86 (0.85-0.87)***  0.89 (0.88-0.90)***  0.98 (0.97-0.99)*** 
Median Income 0.95 (0.93-0.97)***  1.04 (1.01-1.07)**  1.03 (1.01-1.05)** 
DM medication usage         
Diet control - -  - -  - - 
Oral agents only 2.01 (1.81-2.22)***  1.25 (1.07-1.47)**  0.94 (0.86-1.03) 
Injectable agents only 2.59 (2.29-2.93)***  1.20 (0.96-1.50)  1.61 (1.44-1.80)*** 
Oral and injectable agents 1.98 (1.76-2.21)***  0.98 (0.80-1.19)  1.02 (0.92-1.13) 
Other controlled medication         
ACEI*cirrhosis only 0.90 (0.84-0.97)**  0.73 (0.64-0.82)***  0.99 (0.92-1.07) 
ACEI*dual diagnosis 0.76 (0.70-0.82)***  0.83 (0.72-0.95)**  0.90 (0.83-0.97)** 
ARB*cirrhosis only 0.78 (0.71-0.85)***  0.89 (0.77-1.04)  0.93 (0.85-1.02) 
ARB*dual diagnosis 0.83 (0.76-0.91)***  0.82 (0.69-0.97)*  0.95 (0.87-1.03) 
Statin*cirrhosis only 0.44 (0.40-0.48)***  0.38 (0.33-0.45)***  0.57 (0.52-0.62)*** 
Statin*dual diagnosis 0.54 (0.50-0.59)***  0.49 (0.41-0.57)***  0.67 (0.62-0.73)*** 
SBB*cirrhosis only 1.37 (1.29-1.46)***  0.85 (0.76-0.96)**  1.13 (1.06-1.21)*** 
SBB*dual diagnosis 1.30 (1.20-1.41)***  0.95 (0.81-1.11)  1.15 (1.06-1.24)*** 
NSBB*cirrhosis only 2.89 (2.73-3.05)***  1.53 (1.37-1.70)***  1.61 (1.50-1.73)*** 
NSBB*dual diagnosis 1.94 (1.80-2.11)***  1.30 (1.11-1.52)***  1.23 (1.13-1.34)*** 
*P < 0.05; **P < 0.01; ***P < 0.001. HR, hazard ratio; C.I., confidence interval; P, P-value; ACEI, angiotensin-converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker. 
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Figure 3.1 - Patient flow during the study 
 
 
  MarketScan
®
 Commercial Claims and Encounters and 
Medicare Supplemental Databases 2000 - 2013 
Patients with cirrhosis diagnosis  
(n = 307,050) 
Excluded patients who were not continuously 
enrolled 6 months before and after first diagnosis of 
cirrhosis (n = 205,437) 
Patients with cirrhosis diagnosis with the 
inclusion criteria (n = 101,613) 
Excluded 26,516 patients who   
• Were below 18 years old 
• Had decompensation event or dropped out of the 
system prior to the first diagnosis of compensated 
cirrhosis 
• Were prescribed an encephalopathy medication 
• Were diagnosed with HIV 
• Had a liver transplantation prior to the first 
compensated cirrhosis diagnosis 
• Had missing value on region or area-level income 
• Had diagnosis of diabetes after the first diagnosis 
of cirrhosis 
Final sample on patients with cirrhosis 
(n = 75,097) 
Patients with cirrhosis only before 
the censored date/decompensation 
event (n = 52,254)  
Patients who were dually diagnosed with 
cirrhosis and diabetes before the censored 
date/decompensation event (n = 20,477) 
Excluded patients who were in the cirrhosis only 
group but were prescribed with diabetes medication  
(n = 2,366) 
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Figure 3.2 - Survival time until decompensation event among patients with cirrhosis using Kaplan-Meier 
Curves 
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Figure 3.3 - Survival time until decompensation event among patients with ascites using Kaplan-Meier 
Curves 
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Figure 3.4 - Survival time until decompensation event among patients with spontaneous bacterial 
peritonitis using Kaplan-Meier Curves  
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Figure 3.5 - Survival time until decompensation event among patients with variceal bleeding using 
Kaplan-Meier Curves  
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Figure 3.6 - Survival time until decompensation event among patients with hepatic encephalopathy using 
Kaplan-Meier Curves 
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Figure 3.7 - Survival time until decompensation event among patients with hepatocellular carcinoma using 
Kaplan-Meier Curves  
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Figure 3.8 - Survival time until decompensation event among patients with acute renal failure using 
Kaplan-Meier Curves  
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CHAPTER 4. WHICH PHYSICIAN SPECIALTIES TREAT PATIENTS WITH CIRRHOSIS AND 
DIABETES? 
 
BACKGROUND 
Increasingly, patients with multiple chronic conditions are being managed in patient-centered 
medical homes (PCMH)1,2 that seek to provide comprehensive, patient-centered, and coordinated care.3 
Central to the PCMH is coordinating primary and specialty care. For example, receiving care from both 
primary care providers (PCP) and specialists improves preventive care among cancer survivors.4–7 
However, despite the increasing number of patients with multiple chronic conditions,8 little is known about 
the mix of PCPs and specialists treating patients other than cancer survivors.  
In the United States, cirrhosis is the 11th leading cause of death,9 and the mortality rate has 
increased 40% in the past two decades.10 Cirrhosis is an irreversible condition that has two stages: 
compensated (patients with preserved liver function and no major complications) and decompensated 
(patients with major complications that require more intensive care). Because early cirrhosis is often 
asymptomatic, many patients are unaware of their disease11 and, without proper care, are at risk for 
developing comorbidities and complications. One of the most common of these comorbidities is diabetes, 
which afflicts 28-40% of patients with compensated cirrhosis.12–14 Patients dually-diagnosed with 
compensated cirrhosis and diabetes have a higher risk of developing decompensation events, including 
ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatocellular carcinoma, and acute renal 
failure.14 
Patients with both compensated cirrhosis and diabetes may benefit from being managed by a mix 
of PCPs and specialists from gastroenterology and endocrinology. Several studies provide insights into 
the benefits of receiving care from both specialists and PCP among diabetes patients with chronic kidney 
disease,15,16 tuberculosis17 and cancer;4–7,18 however, little is known about patients dually-diagnosed with 
compensated cirrhosis and diabetes.19 Our study seeks to examine what physician specialties treat 
patients dually-diagnosed with compensated cirrhosis and diabetes.  
 
 
 
58 
METHODS 
Data Source and Sample 
MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases 
(Copyright © 2015 Truven Health Analytics Inc. All Rights Reserved) between 2000 and 2013 were used 
for this retrospective cross-sectional study. Enrollees in MarketScan® included employees insured by 
employer-sponsored plans and their dependents, as well as Medicare-eligible retirees with employer-
provided Medicare Supplemental Plans. The sample included all patients 18 years of age or older who 
were enrolled for at least 6 months before and after the first dual diagnosis of compensated cirrhosis and 
diabetes (Figure 4.1). The first dual diagnosis date of compensated cirrhosis and diabetes was defined as 
either the first date of compensated cirrhosis after a diagnosis of diabetes, or vice versa. Both 
compensated cirrhosis and diabetes were defined using the International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM). Using data from the Outpatient Services Tables and Inpatient 
Admissions Tables, compensated cirrhosis was defined as alcoholic cirrhosis of the liver (ICD-9-CM code: 
571.2), cirrhosis (ICD-9-CM code: 571.5), and biliary cirrhosis (ICD-9-CM code: 571.6).20 Diabetes was 
defined as either: 1) two or more different dates of service for a diabetic-related diagnosis (ICD-9-CM 
code: 250.xx) from the Outpatient Services Table or 2) one or more inpatient encounters with an ICD-9-
CM code for diabetes.21 We excluded patients with decompensated cirrhosis (ICD-9-CM code: 789.59, 
567.23, 456.00, 456.10, 456.2x, 572.20, 070.2x, 070.40, 070.44, 070.49, 070.60), acute renal failure 
(ICD-9-CM code: 584.xx), or hepatocellular carcinoma (ICD-9-CM code: 155.xx) diagnosed prior to the 
first dual diagnosis date. In addition, to avoid misclassification, patients who were prescribed an 
encephalopathy drug (Lactulose and Rifaxamin), had a diagnosis of HIV (ICD-9-CM code: 042.xx-044.xx), 
or had a liver transplantation (ICD-9-CM code: V42.7, ICD-9 procedure: 50.5, or CPT code: 47135, 
47136) prior to the first dual diagnosis date were also excluded. The end of the study period was defined 
as the: 1) first drop-out date; 2) date of a serious complication (i.e. decompensation event, hepatocellular 
carcinoma, and acute renal failure); or 3) end of the study period (December 31, 2013). The study was 
exempted by University of North Carolina at Chapel Hill Institutional Review Board (IRB).  
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Type of Physicians 
Physicians who practiced in outpatient settings were identified using the “Provider Type” from the 
MarketScan Outpatient Services Table. Gastroenterologists (GI) were defined as physicians in 
gastroenterology; endocrinologists (ENDO) were defined as physicians in endocrinology and metabolism. 
Because there was no category for PCP, we used a definition based on previous studies:4–7 family 
practice, geriatric medicine, obstetrics/gynecology, internal medicine not elsewhere classified (NEC), 
medical doctor (NEC), and multi-specialty group practice. We categorized patients into four categories 
based on the physician mix visited: (1) PCP with no GI/ENDO, (2) GI/ENDO with no PCP, (3) both PCP 
and GI/ENDO, and (4) neither PCP nor GI/ENDO (Figure 4.1). We summed physician encounters by 
specialty in each year from 2000 to 2013. 
Physician Density 
Previous studies have found that patients residing in higher physician density areas had better 
access to PCPs and specialists.22–24 Therefore, physician density is used as a measure of access in our 
sample. We focused on density of PCPs, GI/ENDOs, and other physicians. MarketScan contain enrollees’ 
five-digit Federal Information Processing Standard (FIPS) codes between year 2000 and 2010, but the 
variable was then dropped due to privacy concerns. For patients who had their first dual-diagnosis of 
compensated cirrhosis and diabetes after 2011, metropolitan statistical area (MSA) was used to identify 
patients’ geographic location. MSA identifies whether patients resided in a metropolitan area, including 
the state and county name. Patients who resided in non-metropolitan areas after 2011 did not have 
county and state information and were dropped. The five-digit FIPS codes for 2001-2010 data, as well as 
state and county (linked through MSA) for 2011-2013 data, were identified with hospital referral regions 
(HRRs) through the Dartmouth Atlas Project (www.dartmouthatlas.org). The Dartmouth Atlas Project 
identified 306 HRRs based on where Medicare patients were admitted for tertiary care for major 
cardiovascular surgeries.25 Physician density per 100,000 residents in each HRR, including PCP, GI, 
ENDO, and other specialties were only provided in 1996, 2006, and 2011. We linked the physician 
density with the closest year: 2000 and 2001 were linked with physician density in 1996; 2002-2008 with 
physician density in 2006; and 2009-2013 with physician density in 2011. If multiple HRRs were linked to 
single patient, weighted physician densities based on the total population in each HRR were calculated.  
 
 
60 
Health Care Utilization 
Annual physician visits and annual health care expenditures for each patient were used as 
indicators of health care utilization. Both variables came from the MarketScan Outpatient Services Table. 
The comparison between annual physician visits and annual health care expenditures provided 
information on whether increased physician visits increased the burden of health care expenditures. 
Physician visits were summed for each physician mix category during the observation period. Total health 
care expenditures were the sum of deductible, coinsurance, coordination of benefits and other savings, 
and the net payments from each outpatient visit. Average physician visits and health care expenditures 
per patient per year were reported. 
Covariates 
Demographic variables, including age, gender, and geographic region, were identified through the 
Annual Enrollment Summary Table. The Elixhauser Comorbidities index26,27 was defined in the six 
months prior to the first dual diagnosis date. To avoid collinearity, diseases related to liver disease and 
diabetes were excluded when calculating the Elixhauser Comorbidity Index; the remaining 28 
comorbidities were summed (0-28). Because socioeconomic status (SES) was not available in the 
database, area-level median income was used as a proxy. Area-level median income provided by the 
Small Area Estimates Branch, U.S. Census Bureau was linked through five-digit FIPS code between 2000 
and 2010 and MSA code between 2011 and 2013.  
Data Analysis 
Our analysis focused on investigating the characteristics that affect dually-diagnosed patients’ 
choice of physician mix categories. We first examined patient characteristics, the distribution of visits to 
physician mix categories, and the number of physician encounters between 2000 and 2013. Patient 
encounters were analyzed separately for additional information. We then compared the percentage and 
average number of annual visits to each physician specialty by physician mix category. Time trends for 
the percentage and the number of visits for physician mix categories were analyzed. Furthermore, to 
understand the characteristics that affect patients’ physician mix category, a multinomial probit model was 
estimated to compare the odds of visiting different physician mix categories, controlling for age, gender, 
geographic location, physician density, number of comorbidities, and area-level median income. Marginal 
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effects on the probability of visiting each physician mix category and confidence intervals (CI) were 
calculated and reported based on the delta method. A p-value < 0.05 was considered statistically 
significant. All analyses were conducted using SAS for Windows, Version 9.4 (SAS Institute Inc, Cary, 
NC, USA) and STATA 14.0 (STATA Corp, College Station, TX, USA). 
RESULTS 
The 22,516 patients (47,985 patient-years) in the final sample had 1,151,542 encounters during 
the 14-year study period. Approximately half of patients (54.0%) were male, 25.6% were over 65 years of 
age. Each patient had an average of approximately two comorbidities besides cirrhosis and diabetes 
(Table 4.1). In addition, each patient had an average of 18.7 months of observation time, with a median of 
11.2 months. Patients who visited GI/ENDO with no PCP had the fewest comorbidities; patients who 
visited PCPs, with or without GI/ENDO, had the most comorbidities.  
During the 14-year study, 92.5% of patients visited a PCP (53.8% visited PCP and GI/ENDO and 
38.7% visited PCP with no GI/ENDO) and 58.6% visited any GI/ENDO (53.8% visited PCP/GI/ENDO and 
4.8% visited GI/ENDO with no PCP). In addition, 2.7% of patients did not visit any PCP, GI, and/or 
ENDO. Interestingly, a dramatic change in visit pattern was observed in 2003 from visiting PCP only to 
both PCPs and specialists; this change flattened after 2006 (Figure 4.2). Overall, the number of patients 
who visited both PCPs and specialists (GI and ENDO) increased more than 70% (24.7% in 2000 and 
42.2% in 2013) during the study period. About 4% of patients in any given year did not visit either PCP or 
GI/ENDO, but the percentage decreased 21% from 2000 to 2013. Overall, a large proportion of patients 
visited PCPs only in any given year throughout the 14 years of observation.  
At the encounter-level, 57.1% of all patient encounters were with PCPs, 5.9% of encounters were 
with GIs, and only 3.0% of encounters were with ENDOs. Other provider encounters included 
cardiovascular disease specialists (6.4%), oncology (4.7%), and ophthalmology (3.4%). The remaining 
provider encounters included a diverse group of specialists, each representing less 3% of all encounters 
(Table 4.2).  
The trend of annual physician visits was very similar among the physician mix categories (Figure 
4.3). On average, patients who visited both PCP and GI/ENDO had the highest number of total physician 
visits, followed by patients who visited PCP with no GI/ENDO. The same pattern can be found in total 
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health expenditures, but the health care expenditure increased steadily over the past decade. 
Interestingly, patients who visited PCPs only had the fewest comorbidities; while the number of 
comorbidities among patients who visited both PCP and GI/ENDO were only slightly higher than the PCP 
only group (Figure 4.4). The average number of comorbidities steadily increased after 2002. 
Patients had an average of 15.0 visits to any PCP, an average of 4.4 visits to any GI/ENDO, and 
an average of 7.2 visits to any other physicians throughout the study period (Figure 4.5). Patients who 
were in PCP/GI/ENDO group had slightly lower average number of PCP visits than the PCP with no 
GI/ENDO group in every year of estimate, but had the highest average number of visits to other physician 
than the rest of the physician mix categories. Among patients who had visited any GI/ENDO, the average 
number of visits was similar between those with and without a PCP visit. 
After adjusting for patient characteristics and physician density, male patients, those with a higher 
number of comorbidities, and those with lower median income had higher probability of visiting PCPs with 
no GI/ENDO; while female patients, those with fewer comorbidities, and those with higher median income 
had higher probability of visiting the specialist with or without PCP (Table 4.3). Moreover, patients who 
resided in higher PCP density areas tend to visit PCP more than any other specialties, while patients who 
resided in higher GI/ENDO density area had higher probability of visiting any GI/ENDO and lower 
probability of visiting any PCP. 
DISCUSSION 
This is the first national study to examine patterns of outpatient care for patients with dually-
diagnosed diabetes and compensated cirrhosis, a group with high and costly health care utilization that is 
challenging to manage. Often, they may be best managed by outpatient PCPs and specialist physicians. 
Previous studies have shown that the role of PCPs in managing patients with compensated cirrhosis was 
to identify risk factors, improve quality and length of life, and prevent patients from complications.28 
Specialists traditionally treat the complications and select patient candidates for liver transplantation when 
necessary.28 One study found that patients had better outcomes when managed by both PCPs and GIs 
when admitted to hospital due to a decompensated cirrhosis event,29 and another showed that local 
access to subspecialty care increases the chance of patients receiving a liver transplant.24  However, we 
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are not aware of any studies investigating the mix of physician specialties treating patients with 
compensated cirrhosis and diabetes.  
We found that more than 90% of these patients visited PCPs; although perhaps not surprising, 
we found that 38.7% of these patients only visited PCPs. In addition, when examining trends in the mix of 
physician visits, more than half of our sample visited PCPs but not any specialists each year. However, 
the percentage of patients visiting a PCP only decreased 22% (from 62.7% in 2000 to 48.6% in 2013), 
while the share of patients who visited both PCPs and specialists increased by over 70% (from 24.7% in 
2000 to 42.2% in 2013). One explanation for this shift in patterns may the increasing emphasis on the 
PCMH: once patients with diabetes are diagnosed with compensated cirrhosis, they are likely to be 
referred to the GI, which could explain the increasing percentage of patients visiting both PCPs and GIs. 
As the number of patients visiting both PCPs and specialists increases, so does the importance of the 
PCMH to coordinate care. Several studies have found that the PCMH model was able to successfully 
reduce cost and ED utilization only among patients with complex chronic conditions.30,31 Therefore, the 
PCMH and other coordinated care models may be especially critical for complex patients such as those in 
our study.  
When viewing the trend of visits to each specialist, the average number of visits to PCPs was 
about ten times higher than the average number of visits to GI/ENDO. However, the mix of physicians 
treating patients in our sample is very different from the mix of physicians found in studies of breast 
cancer6 and colorectal cancer4,5 survivors with comorbid chronic diseases. About one quarter of breast 
cancer survivors visited a PCP, but not an oncologist, while more than half visited both PCPs and 
oncologists.6 Colorectal cancer survivors tended to visit PCPs but not oncologists, although visiting both 
PCPs and oncologists remained the second largest group.4,5 Our study found that during the 14-year 
study period, patients dually-diagnosed with compensated cirrhosis and diabetes commonly visited both 
PCP and specialists, but the distribution changed over time with increased visits to both PCP and 
GI/ENDO.  
The pattern of visiting mix of physician specialties was correlated with age, gender, physician 
density, number of comorbidities, and median income in our study. Although patients who visited a 
GI/ENDO with no PCP seem to have the least number of comorbidities in any given year, they were 
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relatively younger than patients in other physician mix categories. On the other hand, patients who visited 
both PCP and GI/ENDO had the highest total visits and total expenditures, but their average number of 
comorbidities were almost the same as those who visited PCP only. However, this crude result does not 
taken other confounders into consideration, such as age, gender, and other comorbidities, which may be 
biased when assessing the outcome. Therefore, whether these patients had better outcomes as a result 
of visiting both a PCP and GI/ENDO requires further investigation.  
Our study had several limitations. First, our sample included only persons who were enrolled in 
employer-sponsored plans and/or Medicare Supplemental plans; therefore, our findings may not 
generalize to persons who are uninsured or insured with other types of programs. Second, some patients 
were dropped due to incomplete physician density because of the data structure and data linkage. This 
was because we can only access three years of physician density from Dartmouth Atlas of Health Care, 
and these patients were unable to link the corresponding physician density through FIPS and MSA. In 
addition, we were unable to identify their county and state information for patients who were diagnosed 
after 2011 and resided in non-metropolitan areas. However, we tried to obtain the most relevant physician 
density each year by linking the physician density with the closest time period. Finally, MarketScan data 
lack information about important patient characteristics that affect access to care, for example, SES and 
race/ethnicity. Thus, we were unable to consider these variables in our analyses. However, we used area-
level median income as a proxy to estimate SES.   
The prevalence of cirrhosis11 and diabetes32 alone, and in combination33,34 is increasing, as is the 
morbidity, suffering, and health care costs these patients face. By understanding outpatient visit patterns 
among these patients, we can develop appropriate strategies to manage and improve their health. We 
found that the proportion of patients who visited both PCPs and GI/ENDOs increased dramatically in the 
past decade. Although we cannot conclude that these patients received better coordinated care than 
patients who only visited PCPs or GI/ENDOs, this trend towards the involvement of both PCPs and 
GI/ENDOs moves toward the PCMH. Involving both PCPs and specialists increased the likelihood of 
cancer patients’ receiving preventive care;4–7 future research is needed to determine whether patients 
with compensated cirrhosis and diabetes could similarly benefit from visiting both PCPs and specialists. 
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Table 4.1 - Descriptive distribution of patients who were dually diagnosed with compensated cirrhosis and diabetes by physician mix category, 
MarketScan 2000-2013. 
  
Total  PCP with no GI/ENDO  
GI/ENDO with no 
PCP   
PCP and 
GI/ENDO  Other physician 
N %  N %  N %  N %  N % 
Total dual diagnosed patients 22,516 8,717 38.71 1,078 4.79 22,516 8,717 38.71
Gender  
Male 12,151 53.97 4,944 56.72 666 61.78 12,151 53.97 4,944 56.72
Female 10,365 46.03 3,773 43.28 412 38.22 10,365 46.03 3,773 43.28
Age group  
Under 40 785 3.49 337 3.87 46 4.27 785 3.49 337 3.87
40-44 1,029 4.57 431 4.94 47 4.36 1,029 4.57 431 4.94
45-49 2,100 9.33 825 9.46 118 10.95 2,100 9.33 825 9.46
50-54 3,735 16.59 1,322 15.17 177 16.42 3,735 16.59 1,322 15.17
55-59 4,857 21.57 1,687 19.35 239 22.17 4,857 21.57 1,687 19.35
60-64 4,241 18.84 1,630 18.70 231 21.43 4,241 18.84 1,630 18.70
65+ 5,769 25.62 2,485 28.51 220 20.41 5,769 25.62 2,485 28.51
Region  
Northeast 3,131 13.91 1,073 12.31 188 17.44 3,131 13.91 1,073 12.31
Midwest 6,382 28.34 2,863 32.84 195 18.09 6,382 28.34 2,863 32.84
South 11,603 51.53 4,106 47.10 649 60.20 11,603 51.53 4,106 47.10
West 1,400 6.22 675 7.74 46 4.27 1,400 6.22 675 7.74
Comorbidities (mean, SD) 1.88 1.72  1.98 1.79  1.69 1.55  1.88 1.72  1.98 1.79
Median income in 10K (mean, SD) 5.07 1.29  4.99 1.25  5.22 1.28  5.07 1.29  4.99 1.25
Physician encounters (mean, SD) 18.68 21.52  16.19 19.69  5.50 7.74  18.68 21.52  16.19 19.69
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Table 4.2 - Distribution of total physician encounters by specialties, 2000-2013 
  n % 
Total 1,151,542  
Primary Care Physician 657,604 57.11
Cardiovascular Dis/Cardiology 73,235 6.36
Gastroenterology 68,370 5.94
Oncology 54,480 4.73
Ophthalmology 38,715 3.36
Endocrinology & Metabolism 35,196 3.06
Hematology 30,887 2.68
Emergency Medicine 28,512 2.48
Dermatology 22,517 1.96
Urology 21,299 1.85
Rheumatology 16,158 1.40
Pulmonary Disease 15,111 1.31
Neurology 13,393 1.16
Nephrology 13,326 1.16
Physical Medicine & Rehab 12,842 1.12
Otolaryngology 11,612 1.01
Psychiatry 10,271 0.89
Infectious Disease 8,216 0.71
Allergy & Immunology 6,976 0.61
Hospitalist 2,923 0.25
Pediatrician (NEC) 2,296 0.20
Critical Care Medicine 2,209 0.19
Plastic/Maxillofacial Surgery 2,176 0.19
Osteopathic Medicine 1,994 0.17
Preventative Medicine 354 0.03
Proctology 263 0.02
Pediatric Specialist (NEC) 183 0.02
Pediatric Orthopaedics 178 0.02
Neonatal-Perinatal Medicine 105 0.01
Sports Medicine (Pediatrics) 59 0.01
Palliative Medicine 45 0.00
Genetics 34 0.00
Pediatric Urology 3 0.00
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Table 4.3 - Marginal effects on probability of visiting different physician mix categories using multinomial probit model 
  PCP with no GI/ENDO   GI/ENDO with no PCP  PCP and GI/ENDO  Neither PCP nor GI/ENDO
  ME 95% C.I.  ME 95% C.I.  ME 95% C.I.  ME 95% C.I. 
Physician density (per 
100K)          
PCP 0.0009 (0.0005-0.0014)***  -0.0002 (-0.0004-0.0000)*  -0.0006 (-0.0010--0.0001)*  -0.0001 (-0.0003-0.0000) 
GI/ENDO -0.0268 (-0.0360--0.0176)***  0.0069 (0.0028-0.0110)**  0.0163 (0.0069-0.0258)**  0.0035 (0.0004-0.0067)* 
Neither PCP nor 
GI/ENDO 0.0015 (0.0009-0.0021)
***  -0.0001 (-0.0003-0.0002) -0.0013 (-0.0019--0.0007)*** -0.0001 (-0.0003-0.0001) 
Female -0.0475 (-0.0601--0.0348)***  -0.0145 (-0.0202--0.0088)*** 0.0691 (0.0562-0.0820)***  -0.0072 (-0.0115--0.0028)**
Age group            
Under 40 --- ---  --- --- --- --- --- --- 
40-44 -0.0173 (-0.0616-0.0270)  -0.0127 (-0.0318-0.0065)  0.0329 (-0.0130-0.0787)  -0.0029 (-0.0180-0.0121) 
45-49 -0.0428 (-0.0820--0.0037)*  -0.0032 (-0.0195-0.0132)  0.0442 (0.0038-0.0846)*  0.0018 (-0.0112-0.0148) 
50-54 -0.0856 (-0.1224--0.0489)***  -0.0101 (-0.0256-0.0053)  0.1006 (0.0626-0.1385)***  -0.0048 (-0.0172-0.0076) 
55-59 -0.0938 (-0.1298--0.0578)***  -0.0082 (-0.0233-0.0069)  0.1059 (0.0687-0.1431)***  -0.0040 (-0.0161-0.0082) 
60-64 -0.0588 (-0.0952--0.0224)**  -0.0015 (-0.0167-0.0137)  0.0568 (0.0192-0.0944)**  0.0035 (-0.0086-0.0156) 
65+ -0.0226 (-0.0583-0.0132)  -0.0156 (-0.0308--0.0005)*  0.0431 (0.0061-0.0801)*  -0.0049 (-0.0170-0.0072) 
Region            
Northeast --- ---  --- --- --- --- --- --- 
Midwest 0.0602 (0.0347-0.0858)***  -0.0133 (-0.0249--0.0016)*  -0.0421 (-0.0685--0.0158)**  -0.0049 (-0.0137-0.0040) 
South -0.0171 (-0.0414-0.0072)  0.0102 (-0.0004-0.0207)  0.0039 (-0.0210-0.0288)  0.0031 (-0.0051-0.0112) 
West 0.0941 (0.0601-0.1280)***  -0.0111 (-0.0273-0.0050)  -0.0815 (-0.1168--0.0463)***  -0.0014 (-0.0133-0.0104) 
Comorbidities 0.0132 (0.0094-0.0169)***  -0.0031 (-0.0049--0.0014)*** -0.0131 (-0.0170--0.0093)***  0.0031 (0.0019-0.0043)*** 
Median income in 10K -0.0199 (-0.0260--0.0138)***   0.0032 (0.0005-0.0058)*  0.0184 (0.0121-0.0247)***  -0.0017 (-0.0038-0.0004) 
ME: Marginal Effect; *P < 0.05; **P < 0.01; ***P < 0.001 
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Figure 4.1 - Patient flow for selecting dually diagnosed patients 
  
MarketScan
®
 Commercial Claims and Encounters and Medicare 
Supplemental Databases 2000 - 2013 
Patients dually diagnosed with compensated cirrhosis 
and diabetes over 18 years old (n = 112,670) 
Exclude patients who were not continuously enrolled 6 
months before and after first dual diagnosis of compensated 
cirrhosis and diabetes (n = 35,190) 
Patients with dual diagnosis with the 
inclusion criteria (n = 77,480) 
Exclude 54,964 patients who:  
• Had decompensated cirrhosis, acute renal failure, or 
hepatocellular carcinoma  
• Were prescribed an encephalopathy drug 
• Were diagnosed with HIV 
• Had a liver transplantation prior to the first compensated 
cirrhosis diagnosis prior to the first dual diagnosis of 
compensated cirrhosis and diabetes 
Or  
• Had missing value on region or area-level income 
• Had missing information on visited providers 
• Had missing information on provider density 
Final sample on patients dually diagnosed with 
compensated cirrhosis and diabetes (n = 22,516)
a. PCP with  
no GI/ENDO 
(n = 8,717) 
b. GI/ENDO  
with no PCP 
(n = 1,078) 
c. Both PCP 
and 
GI/ENDO  
(n = 12,110) 
d. Neither PCP nor GI/ENDO (n = 611)
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Figure 4.2 - Distribution of physician mix categories among dually diagnosed patients 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
  PCP with no GI/ENDO 62.67 63.66 64.14 66.21 60.02 56.45 52.44 51.36 50.99 50.36 48.90 49.40 49.92 48.60
  GI/ENDO with no PCP 8.00 3.51 4.37 3.61 3.73 3.79 5.65 5.02 6.24 5.45 5.16 5.35 5.06 5.49
  PCP and GI/ENDO 24.67 30.08 30.08 26.86 33.07 36.26 37.96 39.47 38.84 40.06 42.04 41.42 41.49 42.21
  Neither PCP nor GI/ENDO 4.67 2.76 1.41 3.32 3.18 3.50 3.95 4.14 3.94 4.14 3.89 3.82 3.52 3.71
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Figure 4.3 - Average number of annual health care utilization among dually diagnosed patients, by 
physician mix category 
 
 
 
 
 
 
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
  PCP with no GI/ENDO 20.91 18.34 19.64 22.69 20.74 20.26 21.46 22.82 22.32 22.71 22.19 21.44 23.75 22.75
  GI/ENDO with no PCP 7.67 6.93 7.68 8.06 9.43 9.11 10.64 11.13 10.11 11.53 9.06 9.25 9.83 12.94
  PCP and GI/ENDO 18.70 25.34 27.79 27.60 27.80 27.91 28.66 31.60 28.74 31.96 30.96 28.34 29.80 30.10
  Neither PCP nor GI/ENDO 6.29 5.27 4.73 5.52 6.81 7.46 7.45 8.10 10.30 7.12 6.30 7.21 10.31 8.82
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  GI/ENDO with no PCP 0.86 0.53 0.65 0.73 0.79 0.84 1.01 1.32 1.10 1.33 0.85 0.79 0.83 1.46
  PCP and GI/ENDO 1.09 1.89 2.41 2.16 2.42 2.42 2.72 3.14 2.67 3.27 3.22 2.71 2.77 3.05
  Neither PCP nor GI/ENDO 0.37 1.17 0.40 0.64 0.80 0.85 0.84 0.83 1.14 0.84 0.62 1.33 1.30 1.56
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Figure 4.4 - Average age and number of comorbidities by physician mix categories by year 
 
 
 
 
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
  PCP with no GI/ENDO 61.45 61.53 60.84 62.17 63.26 63.01 57.84 59.66 59.67 62.60 60.88 61.18 60.47 61.84
  GI/ENDO with no PCP 64.92 59.42 58.15 58.42 59.88 59.70 57.27 55.30 58.66 58.93 58.91 60.05 58.70 60.44
  PCP and GI/ENDO 61.43 60.61 59.24 62.14 60.40 61.18 57.95 59.13 60.09 62.76 60.43 61.21 60.40 61.19
  Neither PCP nor GI/ENDO 57.86 65.25 55.60 61.00 61.00 63.74 58.50 56.68 60.38 61.48 60.02 61.65 58.13 61.80
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  GI/ENDO with no PCP 0.50 0.67 0.81 0.87 1.00 0.96 1.15 1.17 1.42 1.55 1.82 1.97 1.86 1.78
  PCP and GI/ENDO 1.11 1.52 1.05 1.05 1.16 1.24 1.37 1.30 1.36 1.96 1.69 1.89 1.91 2.05
  Neither PCP nor GI/ENDO 0.57 2.25 0.80 1.16 1.29 1.47 1.20 1.85 1.83 1.99 2.25 2.25 2.18 2.72
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Figure 4.5 - Average number of annual visits to physician specialties among dually diagnosed patients, by 
physician mix category 
 
 
 
*Other physician include cardiologist, oncologist, ophthalmologist, and among all others.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
  PCP with no GI/ENDO 18.86 15.49 15.46 18.98 16.87 14.96 14.68 16.53 16.40 16.03 15.91 15.19 16.96 15.70
  PCP and GI/ENDO 11.00 14.00 13.38 14.45 14.19 14.26 13.55 14.91 13.52 15.15 13.68 13.20 13.63 12.62
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  GI/ENDO with no PCP 3.33 5.14 4.12 3.96 4.52 3.55 4.25 4.89 4.35 4.91 4.55 5.26 5.19 4.53
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  PCP with no GI/ENDO 2.05 2.85 4.17 3.71 3.87 5.31 6.78 6.29 5.92 6.68 6.27 6.25 6.78 7.05
  GI/ENDO with no PCP 4.33 1.79 3.56 4.10 4.91 5.55 6.39 6.23 5.76 6.62 4.51 3.98 4.64 8.41
  PCP and GI/ENDO 3.00 6.72 9.84 8.83 9.74 9.44 10.53 11.80 10.56 11.68 12.06 10.49 11.15 12.39
  Neither PCP nor GI/ENDO 6.29 5.27 4.73 5.52 6.81 7.46 7.45 8.10 10.30 7.12 6.30 7.21 10.31 8.82
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CHAPTER 5. THE IMPACT OF PHYSICIAN SPECIALTY MIX ON THE OUTCOMES OF PATIENTS 
DUALLY-DIAGNOSED WITH COMPENSATED CIRRHOSIS AND DIABETES  
 
BACKGROUND 
Liver cirrhosis is an irreversible chronic condition that affects more than 600,000 Americans1 and 
was the eleventh leading cause of death in the United States in 2012.2 Cirrhosis has two stages: 
compensated (asymptomatic patients with preserved liver function) and decompensated (patients with 
complications such as variceal bleeding, ascites, and hepatic encephalopathy that require more intensive 
medical care). Without proper care, patients with compensated cirrhosis often progress to 
decompensation and experience serious complications such as acute renal failure and hepatocellular 
carcinoma. Once decompensation occurs, the 5-year mortality can reach to 85% without transplantation.3 
Among patients with compensated cirrhosis, up to 70% have co-morbid diabetes.4–7 Determining 
the best practices for managing these complex patients is important given the increasing prevalence of 
cirrhosis1 and diabetes8, as well as those who are dually-diagnosed.9,10 Liu and colleagues (2015) found 
that patients dually-diagnosed with compensated cirrhosis and diabetes were mainly managed by primary 
care physicians (PCPs), although the number of patients who also visited gastroenterologists (GIs) and 
endocrinologist (ENDOs) had increased rapidly in the past decade.11 Receiving care from both PCPs and 
specialty physicians is consistent with efforts to coordinate care through models such as Patient-Centered 
Medical Home (PCMH).12,13 Previous studies have found that receiving care from primary care and 
specialty physicians may improve the quality of care and lower rates of hospitalization among cancer 
patients.14–18 However, whether this is the case for patients dually-diagnosed with compensated cirrhosis 
and diabetes is unknown. Therefore, this study examines whether the mix of physician specialties visited 
is associated with major health events among patients dually diagnosed with compensated cirrhosis and 
diabetes. 
METHODS 
In this retrospective cross-sectional study, we used MarketScan® Commercial Claims and 
Encounters and Medicare Supplemental Databases (Copyright© 2015 Truven Health Analytics Inc. All 
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Rights Reserved) between 2000 and 2013. This database included employees insured by employer-
sponsored plans and their dependents, as well as Medicare-eligible retirees with employer-provided 
Medicare Supplemental Plans.19 Inclusion criteria for this study were: (1) age over 18 years old; (2) 
dually-diagnosed with compensated cirrhosis and diabetes using the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM); and (3) enrolled for at least six months before 
and after the first dual diagnosis date, defined as the first date of either compensated cirrhosis after a 
diagnosis of diabetes or vice versa (Figure 5.1).  
Using data from the MarketScan Outpatient Services Tables and Inpatient Admissions Tables, 
compensated cirrhosis was defined as alcoholic cirrhosis of the liver (ICD-9-CM code: 571.2), cirrhosis 
(ICD-9-CM code: 571.5), and biliary cirrhosis (ICD-9-CM code: 571.6).20 Diabetes was defined as either: 
1) two or more different dates of service for a diabetic-related diagnosis (ICD-9-CM code: 250.xx) from 
the Outpatient Services Table or 2) one or more inpatient encounter with an ICD-9-CM code for 
diabetes21. We excluded patients with any decompensated events prior to the first dual diagnosis date. 
Decompensation events were defined by ICD-9-CM codes for ascites (789.59), spontaneous bacterial 
peritonitis (567.23), variceal bleeding (456.00, 456.10, 456.20, 456.21), hepatic encephalopathy (572.20, 
070.2x, 070.40, 070.44, 070.49, 070.60); hepatocellular carcinoma (HCC) (155.xx)22,23 and acute renal 
failure (584.xx).24,25 In addition, to minimize misclassification, we excluded patients who were prescribed 
an encephalopathy drug (Lactulose and Rifaxamin), had a diagnosis of HIV (ICD-9-CM code: 042.xx-
044.xx), or had a liver transplantation (ICD-9-CM code: V42.7, ICD-9 procedure: 50.5, or CPT code: 
47135, 47136) prior to the first dual diagnosis of compensated cirrhosis and diabetes.  
Measures 
The primary outcome was a composite variable that included a decompensation event (defined 
above) and/or hospitalization during the study period. In addition, patients who filled prescriptions for 
encephalopathy medications (Lactulose and Rifaxamin) during the study period were also defined as 
having hepatic encephalopathy. All-cause hospitalizations included any admission found in the Inpatient 
Admission Information Table.  
The primary independent variable was physician specialty (PCP or specialist), which was 
obtained from the MarketScan Outpatient Services Table. Only physicians practicing in outpatient settings 
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were included. Patients were categorized into one of four groups: PCP visits only; specialty visits only (GI 
or ENDO); both PCP and specialty visits; or neither PCP nor specialty visits.11 Because PCP was not an 
explicit category in the MarketScan data, PCPs were defined as family practice, geriatric medicine 
obstetrics/gynecology, internal medicine not elsewhere classified (NEC), and multi-specialty practice 
medical doctor NEC.14–17  
To address unobserved selection bias that might result from sicker patients visiting both PCPs 
and specialists, physician density served as an instrumental variable (IV). This approach requires two 
assumptions: 1) patients residing in areas with higher physician density of each physician specialist had 
higher chance of visiting them, and 2) physician density is independent of the unobserved severity of 
compensated cirrhosis and diabetes. The Dartmouth Atlas Project was used to calculate physician 
density/100,000 residents based on how Medicare patients were admitted to tertiary care from major 
cardiovascular surgeries.26 Physician density of PCPs, GIs, ENDOs, and other specialties were reported 
in 1996, 2006, and 2011 for each hospital referral region (HRR). Patients’ five-digit Federal Information 
Processing Standard (FIPS) county code and metropolitan statistical area (MSA) code were used to link 
physician density to MarketScan data. Detailed linkage between FIPS/MSA and HRRs were described 
elsewhere.11 Since the physician mix has four categories, we included three physician densities as the 
three IVs: density of PCP, density of GI/ENDO, and density of other physicians.  
Covariates included: (1) patient demographics; (2) comorbidity; (3) severity of diabetes; and (4) 
medications reflecting prognosis. Demographics (age, gender, and geographic region) were identified 
through the Annual Enrollment Summary Table. Because socioeconomic status was not available, area-
level median income was used as a proxy. Area-level median income, provided by the Small Area 
Estimates Branch, U.S. Census Bureau, was linked through the five-digit FIPS code between 2000 and 
2010 and the MSA code between 2011 and 2013. We measured comorbidity during the six months prior 
to the first dual diagnosis date using the Elixhauser Comorbidities index.27,28 To avoid collinearity, 
comorbidities related to liver disease and diabetes were excluded. The remaining 28 comorbidities were 
summed (range: 0-28). For severity of diabetes in the 6 months prior to the first dual diagnosis, patients 
were classified as having: 1) no diabetes (diagnosis of diabetes occurred after the diagnosis of 
compensated cirrhosis); 2) diet controlled; 3) using oral agents only; 4) using injectable agents only; and 
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5) using both oral and injectable agents. Medications that may reflect development of hepatic 
decompensation, renal failure and incident hepatocellular carcinoma were angiotensin-converting enzyme 
inhibitors (ACEI), angiotensin receptor blockers (ARB), statins, selective beta-blocker (SBB), and non-
selective beta-blocker (NSBB). These medications were observed throughout the study period using data 
from the Outpatient Services and Outpatient Drug Claims Table and adjusted in the analyses. 
Statistical Analyses 
We first present patient characteristics and decompensation events and/or hospitalization 
between 2000 and 2013. We then assessed the effect of physician mix on our primary composite 
outcome. The end of the study period was defined as: 1) the first drop-out date; 2) the date of a serious 
complication (i.e. decompensation event, hepatocellular carcinoma, or acute renal failure); or 3) 
December 31, 2013.11 To control for endogeneity of patients’ physician mix, IVs with two-stage residual 
inclusion (2SRI) were used. The first stage was a multinomial probit model comparing the odds of visiting 
different physician mix categories, controlling for age, gender, geographic location, number of 
comorbidities, area-level median income, and medications. Physician density was the IV (i.e., included in 
the first stage but excluded from the second stage equation). Marginal effects and confidence intervals for 
the probability of each physician mix category were reported based on the delta method.29 In addition, the 
strength of the instruments was tested using a F-test of the joint significance of the coefficients for the 
three physician density instruments. Standardized residuals were calculated from the first stage30,31 and 
were included in the second stage logistic regression for the probability of any decompensation event and 
hospitalization. Adjusted odds ratios (ORs) and 95% confidence intervals were reported based on the 
second stage logistic regression after bootstrapping. Endogeneity of physician mix in the outcome 
equation was tested using a F-test of the joint significance of the coefficients of the standardized 
residuals. Results of regular logistic regression and 2SRI on each decompensation event and all-cause 
hospitalization on physician densities were also compared. A P-value < 0.05 was considered statistically 
significant. All analyses were conducted using SAS for Windows, Version 9.4 (SAS Institute Inc, Cary, 
NC, USA) and STATA 14.0 (STATA Corp, College Station, TX, USA).  
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RESULTS 
Among 22,516 eligible patients, 12,592 (55.9%) developed a decompensation event and/or were 
hospitalized after the first date of being dually-diagnosed (Table 5.1). During the 14-year period, 53.8% 
visited both PCP and GI/ENDO, 38.7% visited PCP with no GI/ENDO, 4.8% visited GI/ENDO with no 
PCP, and 2.7% visited neither (Figure 5.1). The median observation time was 11.2 months. Patients who 
visited GI/ENDO with no PCP had the highest percentage of developing any decompensation event 
(40.2%), but had the lowest percentage having any hospitalization prior to any decompensation event 
occurring occurred (20.3%). 
Patients who resided in higher PCP density areas had higher probability of visiting any PCP, 
while patients who resided in higher GI/ENDO density areas had lower probability of visiting any PCP 
(Table 5.2). The joint Wald test on coefficients for the IVs was 49.0 (p < 0.05), indicating the three IVs are 
strong instruments. Females were 7.0% more likely to visit both PCP and GI/ENDO, but less likely to visit 
any other physician mix categories when compared to males (Table 5.2). Older patients were more likely 
to visit PCP and GI/ENDO as well as any other specialties when compared with younger patients. 
Patients who had a higher number of comorbidities or lower median income were more likely to visit 
PCPs, but less likely to visit the specialists (i.e., GI/ENDO). When taking the medications into 
consideration, patients with more severe diabetic conditions were more likely to visit GI/ENDO, with or 
without visiting any PCP.  
The second stage of the 2SRI used logistic regression to model whether dually-diagnosed 
patients developed any decompensation event and/or were hospitalized (Table 5.3). The joint Wald test 
on the coefficients of the residuals in the second stage was 13.2 (P < 0.05) for any decompensation event 
and 18.6 (P < 0.05) in addition to any all-cause hospitalization. These results indicated the physician mix 
categories in the original equation were endogenous. Using the PCP only category as the reference 
group, logistic regression without 2SRI indicated that patients in the other physician mix categories had 
increased risk of developing any decompensation event. However, the results of the logistic regression 
using 2SRI showed that patients who visited both PCP and GI/ENDO had 0.1 times lower odds of 
developing any decompensation event (P < 0.05), and 0.05 times lower odds of experiencing any 
decompensation event and/or hospitalization (P < 0.05). Patients who visited neither PCP nor GI/ENDO 
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had 1.24 times higher risk of developing any decompensation event, and even higher risk of experiencing 
any decompensation event and/or hospitalization after using 2SRI, though the magnitude was not 
statistically significant. In addition, patients who were older, lived in areas with lower median income, had 
more severe diabetic conditions, and were prescribed with SBB and NSBB had statistically significantly 
higher risk of experiencing a decompensation event and/or hospitalization.  
Compared to patients who visited the PCP only, patients who visited both PCP and GI/ENDO had 
higher risk of developing each decompensation event and hospitalization using regular logistic regression 
(Table 5.4). However, using 2SRI, visiting both PCP and GI/ENDO became a protective factor for 
developing hepatic encephalopathy, HCC, acute renal failure, and experiencing any hospitalization 
among dually-diagnosed patients. Although the risk of developing ascites, spontaneous bacterial 
peritonitis, and variceal bleeding remained even higher among patients who visited PCP/GI/ENDO 
relative to PCP only, the magnitudes were not statistically significant. 
DISCUSSION 
Patients dually-diagnosed with compensated cirrhosis and diabetes are complex and may require 
visits to both primary care and specialty physicians to best manage their care. This is the first study to 
examine how the mix of physicians these patients visit affects hospitalizations and decompensation 
events. We found that receiving care from both PCP and GI/ENDO was a protective factor against 
hospitalization and decompensation events including acute renal failure and hepatocellular carcinoma. As 
health care reform emphasizes the PCMH model,12,13 this study provides partial evidence on the 
importance of the managed care by both PCPs and specialists, whether they are coordinated by the 
formal PCMH models. Notably, we used instrumental variables to control for unobserved selection bias, 
which allowed us to address selection bias that may incorrectly assess the effects of physician mix on 
risk.  
To our knowledge, this is the first study to show how the mix of physician specialties affected 
outcomes of patients dually-diagnosed with compensated cirrhosis and diabetes. A previous study has 
shown that PCPs played the main role in managing patients with diabetes.32 However, PCPs and 
specialists played different role in managing patients with cirrhosis. PCPs role in managing patients with 
cirrhosis generally involves identifying risk factors that can improve quality and length of life and reduce 
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complications;33 specialists mainly treat complications and select candidates for liver transplantation when 
necessary.33 One study found that patients admitted with decompensation events had better outcomes 
when managed by both PCPs and GIs;34 and another study showed that patients had increased chance 
of receiving a liver transplant when they have local access to GIs.35 However, no study has focused on 
patients with both compensated cirrhosis and diabetes or used instrumental variables to address 
unobservable confounding factors.  
The secondary goal of this study was to analyze hospitalizations and decompensation events 
separately. We found that patients managed by both PCPs and GI/ENDO had the lowest odds of 
developing any decompensation event and/or being hospitalized. Meanwhile, patients who were only 
managed by GI/ENDO (i.e., no PCP) had the highest odds of experiencing any decompensation event, 
although the risk decreases if included hospitalization. This may because the specialists are able to 
manage some decompensation events (i.e., ascites, HCC, and acute renal failure) and prevent these 
patients from further hospitalization. The pattern was similar when examining hospitalizations and 
decompensation events separately. Our results are similar to the studies of preventive care services 
among colorectal and breast cancer survivors.14–16,36 Hence, patients with complex chronic conditions 
may benefit from care by both generalist and specialist physicians. The findings are able to help with the 
development of further treatment protocols that specify what services a PCP should provide and what 
services a GI/ENDO should provide can be specified and formalized. Diabetes severity was also 
associated with our combined outcome of decompensation events or all-cause hospitalization. Similar to 
a previous study,7 after controlling for patient characteristics, patients with milder disease (no diabetes or 
diabetes with diet control) had the least risk for developing deteriorated health status compared to 
patients on diabetic medications. The finds suggested the importance of managing diabetes at early 
stage, despite the severity of cirrhosis among these dually-diagnosed patients. 
Some limitations to this study should be noted. First, we used ICD-9-CM codes to identify our 
cohort. Although we used a validated strategy,37–40 we could not identify patients with undiagnosed 
disease. Second, if our IV assumptions were violated, we may have overestimated the association 
between physician mix categories and patient outcomes. However, since the magnitude of the protective 
factor for the PCP/GI/ENDO group is large, our results would likely remain in the same direction after 
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controlling for any remaining unobservable bias. Third, the MarketScan database lacks data on patients' 
socioeconomic status, race/ethnicity, family history, and lifestyle (e.g. diet, smoking status), which may be 
important confounders on both health care accessibility and health outcomes. We used an IV approach to 
minimize the bias from unobserved confounding. In addition, area-level median income was used as a 
proxy for socioeconomic status. Fourth, the generalizability of our findings is limited because our sample 
was restricted to persons were enrolled in employer-sponsored plans and/or employer-provided Medicare 
Supplemental plans. Last but not least, our findings can only provide evidence on who these patients 
visited (PCPs or specialists), but cannot tell whether the care these patients received was coordinated 
(like the PCMH model), or even if these patients were in the PCMH model.  
In conclusion, with both the number of cirrhosis and diabetes increasing, dually-diagnosed 
patients are expected to continue to increase. Without proper management, decompensation events can 
easily develop among this group, potentially requiring both hospitalization and intensive care. Our study 
suggests that the collaboration between PCPs and GI/ENDOs is important for patients with multiple 
chronic conditions. Therefore, in order to provide more comprehensive care to patients with multiple 
chronic conditions, collaboration and coordination between PCPs and specialties is critical and essential. 
This evidence supports continued emphasis on improving coordination of care through programs such as 
PCMH.  
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Table 5.1 - Descriptive distribution of dually-diagnosed by physician mix category, MarketScan 2000-2013 
  Total 
(N = 22,516)
PCP with no 
GI/ENDO 
(N = 8,717) 
GI/ENDO 
with no PCP 
(N = 1,078) 
PCP and 
GI/ENDO 
(N = 12,110) 
Other 
physician
(N = 611)
% % % % % 
Total dual diagnosed patients  38.71 4.79 53.78 2.71
Any decompensation/hospitalization 55.92 55.16 50.56 56.81 58.76
Decompensation event 27.39 23.79 40.17 28.63 31.75
Ascites 3.13 2.21 5.94 3.58 2.29
Spontaneous bacterial peritonitis 1.46 1.15 1.76 1.68 1.15
Variceal bleeding 8.38 5.21 17.16 9.98 6.55
Hepatic encephalopathy 12.61 11.32 18.92 12.76 16.86
Hepatocellular carcinoma 4.29 3.65 9.09 4.30 4.58
Acute renal failure 13.55 12.84 15.12 13.85 14.89
Had hospitalization 42.29 43.65 20.32 43.20 43.54
Female 46.03 43.28 38.22 49.03 39.77
Age group      
Under 40 3.49 3.87 4.27 3.14 3.60
40-44 4.57 4.94 4.36 4.33 4.42
45-49 9.33 9.46 10.95 9.01 10.80
50-54 16.59 15.17 16.42 17.72 14.73
55-59 21.57 19.35 22.17 23.20 19.97
60-64 18.84 18.70 21.43 18.49 23.08
65+ 25.62 28.51 20.41 24.12 23.40
Region      
Northeast 13.91 12.31 17.44 14.70 14.73
Midwest 28.34 32.84 18.09 26.37 21.44
South 51.53 47.10 60.20 53.60 58.43
West 6.22 7.74 4.27 5.33 5.40
Elixhauser Comorbidity Index (mean, 
SD) 
1.88 1.98 1.69 1.81 2.22
Median income in 10K (mean, SD) 5.07 4.99 5.22 5.12 5.02
Number of months (mean, SD) 18.68 16.19 5.50 22.32 5.39
Diabetic severity proxy      
No diabetes 27.08 29.59 21.61 25.70 28.31
Diet control 38.42 37.88 41.37 38.25 44.35
Oral agents only 20.27 20.09 18.92 20.73 16.04
Injectable agents only 7.09 6.13 10.30 7.53 6.38
Oral and injectable agents 7.15 6.32 7.79 7.80 4.91
Other controlled medication      
ACEI 27.86 28.63 18.83 28.63 17.51
ARB 15.38 14.10 11.41 17.00 8.35
Statin 25.12 25.36 16.88 26.09 17.02
SBB 21.49 22.50 12.99 21.69 18.00
NSBB 16.06 13.48 17.07 18.01 12.44
SD, standard deviation; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor 
blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker.
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Table 5.2 - Marginal effects on probability of visiting different physician mix categories using multinomial probit model (first stage) 
  PCP with no GI/ENDO  GI/ENDO with no PCP 
  ME 95% C.I.  ME 95% C.I. 
Physician density (per 100K)     
PCP 0.0009 (0.0005-0.0014)*** -0.0002 (-0.0004-0.0000)* 
GI/ENDO -0.0269 (-0.0360--0.0177)*** 0.0068 (0.0027-0.0109)** 
Neither PCP nor GI/ENDO 0.0015 (0.0009-0.0021)*** -0.0001 (-0.0003-0.0002) 
Female -0.0480 (-0.0606--0.0354)*** -0.0147 (-0.0204--0.0091)*** 
Age group     
Under 40 --- --- --- --- 
40-44 -0.0149 (-0.0590-0.0292) -0.0100 (-0.0291-0.0090) 
45-49 -0.0394 (-0.0784--0.0004)* -0.0006 (-0.0168-0.0157) 
50-54 -0.0813 (-0.1180--0.0446)*** -0.0063 (-0.0217-0.0091) 
55-59 -0.0887 (-0.1247--0.0527)*** -0.0034 (-0.0185-0.0116) 
60-64 -0.0529 (-0.0893--0.0166)** 0.0035 (-0.0117-0.0186) 
65+ -0.0160 (-0.0517-0.0197) -0.0104 (-0.0255-0.0048) 
Region     
Northeast --- --- --- --- 
Midwest 0.0618 (0.0362-0.0873)*** -0.0109 (-0.0225-0.0007) 
South -0.0161 (-0.0403-0.0082) 0.0107 (0.0001-0.0212)* 
West 0.0927 (0.0588-0.1266)*** -0.0093 (-0.0255-0.0068) 
Number of comorbidities 0.0137 (0.0100-0.0175)*** -0.0030 (-0.0047--0.0012)** 
Median income in 10K -0.0198 (-0.0259--0.0137)*** 0.0030 (0.0004-0.0056)* 
Diabetes severity proxy     
No diabetes --- --- --- --- 
Diet control -0.0483 (-0.0641--0.0325)*** 0.0110 (0.0037-0.0182)** 
Oral agents only -0.0472 (-0.0662--0.0283)*** 0.0199 (0.0111-0.0288)*** 
Injectable agents only -0.0896 (-0.1166--0.0626)*** 0.0406 (0.0294-0.0518)*** 
Oral and injectable agents -0.0782 (-0.1055--0.0509)*** 0.0298 (0.0177-0.0418)*** 
Other controlled medication     
ACEI 0.0191 (0.0036-0.0346)* -0.0210 (-0.0284--0.0136)*** 
ARB -0.0257 (-0.0442--0.0071)** -0.0141 (-0.0230--0.0053)** 
Statin 0.0093 (-0.0068-0.0255) -0.0144 (-0.0222--0.0067)*** 
SBB 0.0078 (-0.0087-0.0242) -0.0173 (-0.0254--0.0091)*** 
NSBB -0.0803 (-0.0980--0.0625)***  0.0061 (-0.0015-0.0137) 
*P < 0.05; **P < 0.01; ***P < 0.001. ME, marginal effect; 95% C.I., 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker. 
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Table 5.2 - Marginal effects on probability of visiting different physician mix categories using multinomial probit model (first stage) (Cont.) 
  PCP and GI/ENDO  Neither PCP nor GI/ENDO 
  ME 95% C.I.  ME 95% C.I. 
Physician density (per 100K)     
PCP -0.0006 (-0.0011--0.0002)**  -0.0001 (-0.0003-0.0000) 
GI/ENDO 0.0167 (0.0072-0.0261)**  0.0034 (0.0003-0.0066)* 
Neither PCP nor GI/ENDO -0.0013 (-0.0019--0.0007)***  -0.0001 (-0.0003-0.0001) 
Female 0.0696 (0.0567-0.0825)*** -0.0068 (-0.0111--0.0025)** 
Age group     
Under 40 --- --- --- --- 
40-44 0.0262 (-0.0195-0.0718) -0.0012 (-0.0162-0.0138) 
45-49 0.0363 (-0.0040-0.0766) 0.0036 (-0.0093-0.0166) 
50-54 0.0901 (0.0523-0.1280)*** -0.0025 (-0.0149-0.0099) 
55-59 0.0932 (0.0561-0.1303)*** -0.0011 (-0.0132-0.0111) 
60-64 0.0434 (0.0059-0.0810)* 0.0061 (-0.0061-0.0182) 
65+ 0.0288 (-0.0082-0.0658) -0.0024 (-0.0145-0.0097) 
Region     
Northeast --- --- --- --- 
Midwest -0.0483 (-0.0746--0.0220)*** -0.0026 (-0.0114-0.0062) 
South 0.0013 (-0.0235-0.0261) 0.0041 (-0.0041-0.0123) 
West -0.0840 (-0.1192--0.0488)*** 0.0006 (-0.0112-0.0125) 
Number of comorbidities -0.0138 (-0.0176--0.0099)***  0.0030 (0.0018-0.0042)*** 
Median income in 10K 0.0184 (0.0122-0.0247)***  -0.0016 (-0.0037-0.0005) 
Diabetes severity proxy     
No diabetes --- --- --- --- 
Diet control 0.0380 (0.0217-0.0543)*** -0.0007 (-0.0059-0.0045) 
Oral agents only 0.0287 (0.0091-0.0482)** -0.0013 (-0.0081-0.0054) 
Injectable agents only 0.0477 (0.0201-0.0753)** 0.0014 (-0.0079-0.0106) 
Oral and injectable agents 0.0518 (0.0239-0.0797)*** -0.0034 (-0.0135-0.0067) 
Other controlled medication     
ACEI 0.0149 (-0.0011-0.0309) -0.0130 (-0.0188--0.0071)*** 
ARB 0.0551 (0.0361-0.0741)*** -0.0153 (-0.0227--0.0079)*** 
Statin 0.0104 (-0.0062-0.0270) -0.0053 (-0.0113-0.0007) 
SBB 0.0083 (-0.0087-0.0252) 0.0013 (-0.0046-0.0071) 
NSBB 0.0780 (0.0600-0.0960)***  -0.0038 (-0.0102-0.0025) 
*P < 0.05; **P < 0.01; ***P < 0.001. ME, marginal effect; 95% C.I., 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker.  
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Table 5.3 - Logistic regression on decompensation event/hospitalization with and without using 2SRI 
  
Any decompensation event 
  
  
Any decompensation 
event and/or all-cause 
hospitalization (2SRI) Logistic regression   2SRI 
OR 95% C.I.   OR 95% C.I.   OR 95% C.I. 
Physician mix category        
PCP only --- ---   --- ---   --- --- 
GI/ENDO only 2.13 (1.86-2.44)***   1.43 (0.85-2.40)   0.93 (0.54-1.59) 
PCP/GI/ENDO 1.28 (1.20-1.37)***   0.10 (0.01-0.78)*   0.05 (0.01-0.42)** 
Neither PCP nor GI/ENDO 1.49 (1.25-1.79)***   1.15 (0.53-2.48)   1.93 (0.88-4.24) 
Female 0.77 (0.72-0.81)***  0.91 (0.77-1.07) 1.04 (0.89-1.22) 
Age group        
Under 40 --- ---  --- --- --- --- 
40-44 1.55 (1.18-2.03)**  1.65 (1.23-2.21)** 1.16 (0.91-1.49) 
45-49 1.99 (1.56-2.53)***  2.17 (1.64-2.87)*** 1.13 (0.90-1.42) 
50-54 2.61 (2.07-3.28)***  3.26 (2.37-4.49)*** 1.66 (1.26-2.19)*** 
55-59 3.00 (2.40-3.77)***  3.79 (2.76-5.21)*** 1.77 (1.35-2.33)*** 
60-64 2.77 (2.20-3.48)***  3.09 (2.36-4.05)*** 1.40 (1.12-1.76)** 
65+ 3.37 (2.69-4.22)***  3.58 (2.77-4.63)*** 1.97 (1.60-2.42)*** 
Region        
Northeast --- ---  --- --- --- --- 
Midwest 1.40 (1.26-1.57)***  1.20 (1.01-1.42)* 1.21 (1.03-1.42)* 
South 1.34 (1.20-1.49)***  1.37 (1.21-1.54)*** 1.32 (1.19-1.48)*** 
West 1.46 (1.25-1.70)***  1.15 (0.89-1.49) 1.16 (0.91-1.48) 
Number of comorbidities 0.98 (0.96-1.00)*  0.95 (0.91-0.98)** 1.00 (0.97-1.04) 
Median income in 10K 0.95 (0.92-0.97)***  0.99 (0.94-1.04) 0.94 (0.90-0.99)* 
Diabetic severity proxy        
No diabetes --- ---  --- --- --- --- 
Diet control 0.96 (0.89-1.04)  1.07 (0.95-1.20) 1.43 (1.28-1.61)*** 
Oral agents only 1.19 (1.09-1.30)***  1.30 (1.15-1.46)*** 1.25 (1.12-1.41)*** 
Injectable agents only 1.32 (1.17-1.50)***  1.52 (1.28-1.80)*** 1.72 (1.46-2.03)*** 
Oral and injectable agents 1.42 (1.25-1.61)***  1.64 (1.37-1.97)*** 1.50 (1.26-1.79)*** 
Other controlled medication        
ACEI 0.84 (0.78-0.91)***  0.86 (0.79-0.94)** 1.09 (1.00-1.18) 
ARB 0.85 (0.78-0.93)***  0.97 (0.84-1.12) 1.14 (1.00-1.31) 
Statin 0.58 (0.53-0.63)***  0.59 (0.53-0.65)*** 0.79 (0.72-0.86)*** 
SBB 1.27 (1.17-1.37)***  1.28 (1.17-1.40)*** 1.65 (1.52-1.80)*** 
NSBB 2.30 (2.13-2.49)***  2.81 (2.35-3.36)*** 2.83 (2.37-3.39)*** 
Residual of PCP/GI/ENDO --- ---  1.09 (0.98-1.22) 0.99 (0.88-1.11) 
Residual of GI/ENDO only --- ---  3.55 (1.28-9.86)* 4.38 (1.60-11.93)** 
Residual of Neither PCP nor 
GI/ENDO --- ---   1.05 (0.92-1.19)   0.92 (0.81-1.05) 
*P < 0.05; **P < 0.01; ***P < 0.001.  
OR, odds ratio; 95% C.I., 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; 
ARB, angiotensin receptor blockers; SBB, selective beta-blocker; NSBB, non-selective beta-blocker.
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Table 5.4 - Logistic regression on each decompensation event and hospitalization with and without using 2SRI 
  Ascites  
Spontaneous Bacterial 
Peritonitis   Variceal Bleeding  
Hepatic 
Encephalopathy 
  OR 95% C.I. P  OR 95% C.I. P   OR 95% C.I. P  OR 95% C.I. P 
Regular logistic regression*              
PCP only --- --- --- --- --- ---  --- --- --- --- --- --- 
GI/ENDO only 2.32 (1.73-3.12) 0.00 1.33 (0.81-2.19) 0.27  3.35 (2.77-4.06) 0.00 1.73 (1.46-2.06) 0.00
PCP/GI/ENDO 1.55 (1.30-1.85) 0.00 1.43 (1.12-1.82) 0.00  1.92 (1.72-2.16) 0.00 1.09 (1.00-1.19) 0.06
Neither PCP nor GI/ENDO 0.94 (0.54-1.63) 0.82 0.90 (0.41-1.95) 0.79  1.21 (0.86-1.70) 0.27 1.65 (1.31-2.08) 0.00
Logistic regression with 2SRI*              
PCP only --- --- --- --- --- ---  --- --- --- --- --- --- 
GI/ENDO only 1.84 (0.57-5.95) 0.31 0.53 (0.11-2.57) 0.43  1.32 (0.70-2.49) 0.40 1.06 (0.58-1.95) 0.86
PCP/GI/ENDO 31.20 (0.40-2456.01) 0.12 5.28 (0.02-1575.92) 0.57  15.31 (0.88-265.72) 0.06 0.03 (0.00-0.47) 0.01
Neither PCP nor GI/ENDO 0.58 (0.04-8.21) 0.69  0.35 (0.01-10.57) 0.55   2.10 (0.48-9.10) 0.32  1.85 (0.68-5.07) 0.23
              
  Hepatocellular Carcinoma  Acute Renal Failure   Hospitalization    
  OR 95% C.I. P  OR 95% C.I. P   OR 95% C.I. P    
Regular logistic regression*              
PCP only --- --- --- --- --- ---  --- --- ---    
GI/ENDO only 2.32 (1.82-2.95) 0.00 1.27 (1.06-1.52) 0.01  0.36 (0.30-0.42) 0.00    
PCP/GI/ENDO 1.19 (1.03-1.37) 0.02 1.11 (1.02-1.21) 0.01  1.01 (0.95-1.07) 0.79    
Neither PCP nor GI/ENDO 1.22 (0.82-1.82) 0.34 1.21 (0.95-1.52) 0.12  1.05 (0.89-1.24) 0.58    
Logistic regression with 2SRI*              
PCP only --- --- --- --- --- ---  --- --- ---    
GI/ENDO only 2.69 (1.10-6.58) 0.03 1.05 (0.55-1.99) 0.89  0.36 (0.19-0.68) 0.00    
PCP/GI/ENDO 0.03 (0.00-0.89) 0.04 0.08 (0.01-0.68) 0.02  0.05 (0.01-0.33) 0.00    
Neither PCP nor GI/ENDO 0.38 (0.06-2.52) 0.32  0.95 (0.34-2.66) 0.93   1.93 (0.91-4.10) 0.09    
*Other controlled variables were the same as listed in Table 5.3. 
OR, odds ratio; 95% C.I., 95% confidence interval 
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Figure 5.1 - Patient flow for selecting dually diagnosed patients 
  
MarketScan
®
 Commercial Claims and Encounters and Medicare 
Supplemental Databases 2000 - 2013 
Patients dually diagnosed with compensated cirrhosis 
and diabetes over 18 years old (n = 112,670) 
Exclude patients who were not continuously enrolled 6 
months before and after first dual diagnosis of compensated 
cirrhosis and diabetes (n = 35,190) 
Patients with dual diagnosis with the 
inclusion criteria (n = 77,480) 
Exclude 54,964 patients who:  
• Had decompensated cirrhosis, acute renal failure, or 
hepatocellular carcinoma  
• Were prescribed an encephalopathy drug 
• Were diagnosed with HIV 
• Had a liver transplantation prior to the first compensated 
cirrhosis diagnosis prior to the first dual diagnosis of 
compensated cirrhosis and diabetes 
Or  
• Had missing value on region or area-level income 
• Had missing information on visited providers 
• Had missing information on provider density 
Final sample on patients dually diagnosed with 
compensated cirrhosis and diabetes (n = 22,516)
a. PCP with  
no GI/ENDO 
(n = 8,717) 
b. GI/ENDO  
with no PCP 
(n = 1,078) 
c. Both PCP 
and 
GI/ENDO  
(n = 12,110) 
d. Neither PCP nor GI/ENDO (n = 611)
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CHAPTER 6. DISCUSSION 
 
CONCLUSIONS 
The overall objectives of this dissertation were to: determine the effect of diabetes among 
patients with compensated cirrhosis, describe who treats this complex group, and estimate the impact of 
visiting different physician specialties on the likelihood of a patient experiencing a decompensation event 
or hospitalization. My central hypothesis is that dually-diagnosed patients have lower likelihood of 
decompensation events and all-cause hospitalizations when receiving multi-disciplinary care from PCP, 
GI and/or ENDO. We found that dual-diagnosed patients had a higher chance of any decompensation 
event than those who only had compensated cirrhosis. These complex patients were managed mainly by 
PCPs, though there is an increased trend of dually-diagnosed patients also visiting specialists in recent 
years. Lastly and most importantly, patients with multiple chronic conditions have better outcomes when 
treated by both PCP and specialists.  
Aim 1 examined the risk of decompensation among a large, national sample of employee-
sponsored insured patients dually-diagnosed with compensated cirrhosis and diabetes. I hypothesized 
that patients with both compensated cirrhosis and diabetes were more likely to experience a 
decompensation event than patients diagnosed only with compensated cirrhosis. Consistent with my 
hypothesis, cirrhosis patients who also had diabetes had an increased risk for each category of clinical 
decompensation events. Moreover, we found a gradient of risk from patients who were diet-controlled 
diabetes to those on oral medications and patients on injectable medications among dually-diagnosed 
patients. 
Aim 2 focused on how patients with dually-diagnosed compensated cirrhosis and diabetes were 
managed between 2000 and 2013. I hypothesized that regardless of the complexity of these patients’ 
health conditions, a large group of patients did not receive care from both PCPs and GI/ENDOs. We 
found that although the percentage of patients who were managed by both PCPs and GI/ENDOs 
increased in the past decade, there was still a large proportion of patients who visited only PCPs. 
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Although we cannot conclude that these patients received better coordinated care than patients who only 
visited PCPs or GI/ENDOs, this trend towards the involvement of both PCPs and GI/ENDOs suggests 
that PCMH initiatives will be important for these patients.  
In Aim 3, I tested the hypothesis that patients who were treated by both PCPs and GI/ENDOs had 
the lowest likelihood of experiencing a decompensation event and/or all-cause hospitalization. We found 
that visiting both PCPs and GI/ENDOs was a risk factor for poor outcomes; however, when using 
instrumental variables, it was a protective factor. This is because patients who visited specialists may be 
sicker and require more medical attention than those who visited PCPs only, which introduced potential 
selection bias. However, using instrumental variables is able to control for those unobserved confounders, 
and the results of visiting both PCPs and GI/ENDOs being a protective factor is more reliable. Moreover, 
patients with compensated cirrhosis and diabetes who were managed by both PCPs and GI/ENDOs had 
the lowest odds of developing any decompensation event and/or all-cause hospitalization. This may be 
because patients who were managed by both PCPs and GI/ENDOs had more comprehensive care than 
visiting to PCPs only, and thus, were able to prevent them from deteriorated outcome. This study extends 
the findings from Aim 2 and provides further evidence on the importance of the multi-specialty care 
between PCP and specialists, even if they are not yet coordinated by the system. 
POLICY AND CLINICAL RELEVANCE 
As cirrhosis and diabetes become more common,1,2 the prevalence of overall clinical 
decompensation events is expected to increase in the near future.3,4 Clinical decompensation events 
usually require admission to the hospital and frequently to the intensive care unit. These events are 
expensive and can be deadly. Results from Aim 1 and Aim 3 show that diabetes severity is one important 
indicator of whether patients will develop any deteriorated outcomes. Hence, adding screening for 
diabetes to cirrhosis guidelines may prove to be worthwhile. As we found a gradient of risk from diet 
controlled diabetes to patients on oral medications to patients on injectable medications, it may also be 
worthwhile to tighten regulation of glucose levels among patients already diagnosed with diabetes; 
analogous to diabetes control recommendations that already exist in the care of patients with 
cardiovascular disease.5  
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Results from Aim 2 found that the proportion of patients who visited both PCPs and GI/ENDOs 
increased dramatically in the past decade. Although we cannot conclude that these patients received 
better coordinated care than patients who only visited PCPs or GI/ENDOs, this study indicated a trend 
towards the involvement of both PCPs and GI/ENDOs, as is now emphasized in the PCMH model. With 
this in mind, more appropriate strategies need to be developed and implemented to manage and improve 
these patients’ health. Furthermore, the results from Aim 3 provide extended evidence on the importance 
of the multi-specialty care between PCP and specialists when managing dually-diagnosed patients. 
Consistent with previous studies,6–10 multi-disciplinary care can be very beneficial to patients with multiple 
chronic conditions. This also urges the formalization of treatment protocols that specify each specialty’s 
role when treating patients with multiple chronic conditions.  
In addition, the use of physician density as an instrumental variable to assess outcomes among 
dually-diagnosed patients seems to be able to capture a large proportion of unobservable confounding 
factors. One previous study had suggested to use physician supply as an instrument to assess whether 
access to care and health outcome would improve.11 By using physician density as an analogous to 
physician supply, this strategy provides the opportunity to assess health outcomes among patients with 
multiple chronic conditions who were managed by different physician specialties. 
LIMITATIONS 
Several limitations should be noted in all three aims. First, undiagnosed compensated cirrhosis or 
diabetes may not be captured. However, this was addressed as best as we could by using validated ICD-
9-CM codes from the literature.12–15 Second, MarketScan data lacks information on patients' SES, 
race/ethnicity, family history, and lifestyle (e.g. diet, smoking status), which may be important confounders 
to both cirrhosis and diabetes. Area-level income was used as a proxy for SES and alcohol abuse was 
included in the Elixhauser comorbidity index. In addition, to minimize the bias, instrumental variables 
accounted for unobserved confounding between the missing variables and access in Aim 3. Third, lab 
results that measure severity of cirrhosis and diabetes are not available. We have excluded prevalent 
decompensation events to ensure that only patients with compensated cirrhosis were captured at study 
entry. In addition, we used diabetic medication to reflect the difficulty of getting patients under diabetic 
control (diet control, oral medication, injectable medication, and both). Fourth, although we can describe 
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patterns of visits, there is no way to determine the extent to which care was coordinated across providers. 
Finally, the sample in this project was drawn from persons who were enrolled in employer-sponsored 
plans and/or employer-provided Medicare Supplemental plans. Patients in any other insurance programs 
may have very different physician visit patterns. Therefore, the findings may not be generalizable to 
people who are in the Medicaid program, other public programs, individual markets and health care 
exchanges, or the uninsured. 
A few additional limitations apply to Aims 2 and 3. First, some patients were dropped due to 
incomplete physician density because of the data structure and data linkage. This was because I was 
only able to access three years (1996, 2006, and 2011) of physician density using HRRs from the 
Dartmouth Atlas of Health Care, and some patients were unable to be linked the corresponding physician 
density from HRRs through FIPS and MSA if they were not in those three years due to the changes of 
HRR, FIPS, or MSA over time. In addition, for patients who were diagnosed after 2011 and resided in 
non-metropolitan areas, I was unable to identify their county and state information. However, I tried to 
obtain the most relevant physician density each year by linking the physician density in the nearest year. 
Second, there is a possibility my IV assumptions were violated and thus, the correlation between 
physician mix categories and patient outcomes may be biased. However, since the magnitude of the 
protective factor for the PCP/GI/ENDO group is large, it would require a strong correlation between the 
physician mix categories and any remaining unobserved confounder to change the direction of the 
results.  
FUTURE DIRECTIONS 
Based on the existing and forecasted burden of patients with cirrhosis, improving management of 
dually-diagnosed patients’ health is a major challenge. Our study found that managed by both PCPs and 
GI/ENDOs had the lowest risk of deteriorated outcome, but whether the care is coordinated is unknown.  
The emergence of electronic health records in recent years may facilitate coordination of care between 
PCPs and specialists. If so, treatment protocols that specify what services a PCP and a GI/ENDO should 
provide can be specified and formalized. With the Triple Aim of healthcare reform, coordinated care 
across primary care and specialist physicians have the potential to improve patient outcomes with 
reduced healthcare expenditures. By using electronic health records, the coordination between PCPs and 
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the physician specialists can be studied and readily used as the evidence to support PCMHs. Although 
my study found that visiting both PCPs and GI/ENDOs decreased the risk of developing any clinical 
decompensation event and/or any hospitalization, the effect of multi-disciplinary team care on different 
underlying etiologies among these patients may differ, and thus, should also be discussed and advised in 
future work.   
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